Adeptus Health (ADPTQ) 10-K 27 Feb 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
In Millions, except Share data, unless otherwise specified	Dec. 31, 2014	Jun. 30, 2014	Feb. 15, 2015
Entity Registrant Name	Adeptus Health Inc.
Entity Central Index Key	1602367
Document Type	10-K
Document Period End Date	31-Dec-14
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Public Float		$143
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Common Class A [Member]
Entity Common Stock, Shares Outstanding			9,861,930
Common Class B [Member]
Entity Common Stock, Shares Outstanding			10,741,839

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets
Cash	$2,002	$11,495
Restricted cash	4,795	294
Accounts receivable, less allowance for doubtful accounts of $13,068 and $5,295, respectively	37,422	15,887
Other receivables and current assets	17,137	3,901
Medical supplies inventory	4,287	1,494
Total current assets	65,643	33,071
Property and equipment, net	93,892	62,087
Investment in unconsolidated joint venture	2,100
Deposits	1,772	750
Deferred tax asset	34,084
Intangibles, net	20,015	21,795
Goodwill	61,009	61,009
Other long-term assets	4,303	4,580
Total assets	282,818	183,292
Current liabilities
Accounts payable and accrued expenses	25,420	15,207
Accrued compensation	13,521	9,158
Current maturities of long-term debt	1,816	504
Current maturities of capital lease obligations	81	58
Deferred rent	607	497
Total current liabilities	41,445	25,424
Long-term debt, less current maturities	104,982	75,000
Payable to related parties pursuant to tax receivable agreement	30,039
Capital lease obligations, less current maturities	4,056	3,849
Deferred rent	2,416	368
Total liabilities	182,938	104,641
Commitments and contingencies
Shareholders'/Owners' Equity
Owners' equity		78,651
Preferred stock	0
Additional paid-in capital	51,238
Accumulated other comprehensive loss	-74
Accumulated deficit	-3,351
Non-controlling interest	51,861
Total equity	99,880	78,651
Total liabilities and owners'/shareholders' equity	282,818	183,292
Common Class A [Member]
Shareholders'/Owners' Equity
Common Stock	98
Common Class B [Member]
Shareholders'/Owners' Equity
Common Stock	$108

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$13,068	$5,295
Preferred stock, par value	$0.01
Preferred stock, shares authorized	10,000,000
Preferred stock, shares issued	0
Preferred stock, shares outstanding	0
Common stock, shares issued	4,900,000
Common stock, shares outstanding	4,895,521
Common Class A [Member]
Common stock, par value	$0.01
Common stock, shares authorized	50,000,000
Common stock, shares issued	9,845,016
Common stock, shares outstanding	9,845,016
Common Class B [Member]
Common stock, par value	$0.01
Common stock, shares authorized	20,000,000
Common stock, shares issued	10,781,153
Common stock, shares outstanding	10,781,153

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue
Patient service revenue	$80,290	$66,533	$51,946	$44,529	$38,885	$25,947	$26,831	$23,297	$243,298	$114,960	$80,977
Provision for bad debt	-10,234	-8,934	-7,708	-5,748	-5,173	-2,310	-2,333	-2,261	-32,624	-12,077	-8,376
Net patient service revenue	70,056	57,599	44,238	38,781	33,712	23,637	24,498	21,036	210,674	102,883	72,601
Management and contract services revenue	20								20
Total net operating revenue	70,076	57,599	44,238	38,781	33,712	23,637	24,498	21,036	210,694	102,883	72,601
Equity in earnings of unconsolidated joint venture									-900
Operating expenses:
Salaries, wages and benefits									136,498	65,244	41,754
General and administrative									37,604	17,436	12,805
Other operating expenses									27,329	11,185	7,493
Loss (gain) from the disposal or impairment of assets									-42	207	652
Depreciation and amortization									15,037	7,920	4,640
Total operating expenses									216,426	101,992	67,344
(Loss) income from operations	-139	-1,079	-5,072	-341	504	-599	1,401	-415	-6,632	891	5,257
Other (expense) income:
Interest expense									-11,966	-2,827	-1,056
Change in fair market value of derivatives										112	-533
Write-off of deferred loan costs										-440
Total other (expense)									-11,966	-3,155	-1,589
Loss before (benefit) provision for income taxes									-18,598	-2,264	3,668
(Benefit) provision for income taxes									-1,326	720	467
Net loss	-1,477	-3,598	-9,429	-2,767	-1,974	-1,511	1,336	-835	-17,272	-2,984	3,201
Less: Net loss attributable to the non-controlling interest	-1,739	-2,001	-7,413	-2,767	-1,974	-1,511	1,336	-835	-13,921	-2,984	3,201
Net loss attributable to Adeptus Health Inc.	$262	($1,597)	($2,016)						($3,351)
Net loss per share of Class A common stock:
Basic (in dollars per share)									($0.34)
Diluted (in dollars per share)									($0.34)
Weighted average shares of Class A common stock:
Basic (in shares)									9,845,016
Diluted (in shares)									9,845,016
Common Class A [Member]
Net loss per share of Class A common stock:
Basic (in dollars per share)									($0.34)
Diluted (in dollars per share)									($0.34)
Weighted average shares of Class A common stock:
Basic (in shares)									9,845,016
Diluted (in shares)									9,845,016

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Comprehensive Income [Abstract]
Net loss	($3,351)
Less: Net loss attributable to the non-controlling interest	-13,921	-2,984	3,201
Net (loss) income	-17,272	-2,984	3,201
Other comprehensive loss, net of tax:
Unrealized loss on interest rate contract-parent	-74
Unrealized loss on interest rate cap	-74
Comprehensive loss	-3,425
Comprehensive loss - noncontrolling interest	-13,921	-2,984	3,201
Comprehensive loss including portion attributable to noncontrolling interest	($17,346)	($2,984)	$3,201

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS'/OWNERS' EQUITY (USD $)	Adeptus Health L L C Equity [Member]	Parent [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Common Stock [Member]	Additional Paid In Capital [Member]	Additional Paid In Capital [Member]	Accumulated Deficit [Member]	Accumulated Net Gain Loss From Designated Or Qualifying Cash Flow Hedges [Member]	Noncontrolling Interest [Member]	Common Class A [Member]	Common Class B [Member]	Total
In Thousands, except Share data	USD ($)	USD ($)	Common Class A [Member]	Common Class A [Member]	Common Class A [Member]	Common Class B [Member]	Common Class B [Member]	USD ($)	Certain employees [Member]	USD ($)	USD ($)	USD ($)	USD ($)			USD ($)
			Non Employee Directors [Member]	Certain employees [Member]	USD ($)	Certain employees [Member]	USD ($)		USD ($)
						USD ($)
Balance at Dec. 31, 2011	$76,969							$76,969
Issuance of units bClass A (in units)	1,120,000							1,120,000
Stock subscriptions	-250							-250
Net (loss) income	3,201							3,201								3,201
Capital contribution	4,114							4,114
Distributions to existing owners	-2,673							-2,673
Stock based compensation	253							253
Net loss prior to reorganization	3,201							3,201								3,201
Balance at Dec. 31, 2012	82,734							82,734
Stock subscriptions	83							83
Net (loss) income	-2,984							-2,984								-2,984
Stockbbased compensation	586							586
Distributions to existing owners	-1,768							-1,768
Net loss prior to reorganization	-2,984							-2,984								-2,984
Balance at Dec. 31, 2013	78,651							78,651								78,651
Balance at Dec. 31, 2013																78,651
Net (loss) income	-7,093							-7,093								-17,272
Capital contribution	167							167
Distributions to existing owners	-483							-483
Stock based compensation	316							316
Net loss prior to reorganization	-7,093							-7,093								-17,272
Dividends paid to existing owners	-60,000							-60,000
Issuance of Class A shares in IPO	-311	96,536			53			96,225		96,483
Issuance of Class A shares in IPO, shares					5,321,414									4,900,000		735,000
Investment of merged entity into Class A shares	-3,307	3,307			45					3,262
Increase In Shares By Investment Of Merged Entity					4,474,107
Issuance of Class A shares to directors			13,639
Issuance of Class A shares				35,856		39,314
Issuance of Class A shares						1			-1
Issuance of Class B shares in Reorganization and Offering	-7,940	7,940					107			7,833
Issuance of Class B shares in Reorganization and Offering - Shares							10,741,839
Impact of non-controlling interest upon reorganization		-58,687								-58,687			58,687
Effects of Tax Receivable Agreement (See Note 12)		1,992						1,992		1,992
Adjustment to true up tax effects of merger and reorganization		-343						-343		-343
Stock-based compensation subsequent to IPO		699						699		699
Unrealized loss on interest rate contract		-74						-74				-74				-74
Net loss subsequent to IPO		-3,351						-10,177			-3,351		-6,826
Common Stock, Shares, Outstanding					9,845,016		10,781,153							9,845,016	10,781,153	4,895,521
Balance at Dec. 31, 2014		$48,019			$98		$108	$99,880		$51,238	($3,351)	($74)	$51,861			$99,880

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities:
Net loss	($17,272)	($2,984)	$3,201
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Loss (gain) from the disposal or impairment of assets	-42	207	652
Change in fair market value of derivatives		-112	533
Depreciation and amortization	15,037	7,920	4,640
Deferred tax expense	-2,147
Amortization of deferred loan costs	891	293	73
Provision for bad debt	32,624	12,077	8,376
Equity in loss of unconsolidated joint venture	900
Write-off of deferred loan costs		440
Stock-based compensation	1,015	586	253
Changes in operating assets and liabilities:
Restricted cash	-4,501	-294
Accounts receivable	-54,159	-18,107	-9,867
Other receivables and current assets	-8,248	-1,757	-234
Medical supplies inventory	-2,793	-850	-73
Other long-term assets	63	-79
Accounts payable and accrued expenses	7,413	5,632	180
Accrued compensation	4,363	3,883	3,166
Deferred rent	2,158	17	508
Net cash (used in) provided by operating activities	-24,698	6,872	11,408
Cash flows from investing activities:
Cash paid for acquisition (net of cash acquired)			-3,848
Investment in unconsolidated joint venture	-3,000
Deposits	-1,022	-413	-185
Proceeds from sale of property and equipment	2,003	1,814
Capital expenditures	-47,429	-46,048	-11,504
Net cash used in investing activities	-49,448	-44,647	-15,537
Cash flows from financing activities:
Proceeds from initial public offering, net of underwriters fees and expenses	96,226
Proceeds from long-term borrowings	99,457	102,000	25,700
Payment of deferred loan costs	-751	-4,954	-354
Payments on borrowings	-70,380	-50,855	-26,776
Payment of capital lease obligations	-57	-5	-103
Payment to terminate interest rate swap		-421
Payments of dividends	-60,000
Distribution to owners	-9	-33	-631
Contribution from original owner	167	83	870
Capital contributions			4,114
Net cash provided by financing activities	64,653	45,815	2,820
Net increase (decrease) in cash	-9,493	8,040	-1,309
Cash, beginning of period	11,495	3,455	4,764
Cash, end of period	$2,002	$11,495	$3,455

ORGANIZATION

ORGANIZATION	12 Months Ended
	Dec. 31, 2014
ORGANIZATION
ORGANIZATION	NOTE 1—ORGANIZATION
	Adeptus Health Inc. (the "Company") was incorporated as a Delaware corporation on March 7, 2014 for the purpose of facilitating an initial public offering of common equity. The Company is a holding company with its sole material asset being a controlling equity interest in Adeptus Health LLC. As the sole managing member of Adeptus Health LLC, the Company operates and controls all of the business and affairs of Adeptus Health LLC and, through Adeptus Health LLC and its subsidiaries, conducts its business. Prior to the initial public offering, the Company had not engaged in any business or other activities except in connection with its formation and the initial public offering.
	Adeptus Health LLC or its predecessors began operations in 2002 and owns and operates First Choice Emergency Rooms, the largest network of independent freestanding emergency rooms in the United States, delivering both major and minor emergency medical services for adult and pediatric patients. First Choice Emergency Rooms has experienced rapid growth in recent periods, growing from 14 facilities at the end of 2012 to 26 facilities at the end of 2013, and to 55 facilities as of December 31, 2014. The Company’s facilities are currently located in the Houston, Dallas/Fort Worth, San Antonio and Austin, Texas markets; as well as in Colorado Springs and Denver, Colorado; and Phoenix, Arizona.
	On June 24, 2014, the Company’s registration statement on Form S-1 (File No. 33-196142) relating to its initial public offering of Class A common stock was declared effective by the Securities and Exchange Commission (“SEC”). The Company sold 4,900,000 shares of Class A common stock in its public offering.  An additional 735,000 shares were sold to the public, of which 313,586 shares were sold by a significant stockholder and 421,414 shares were sold by the Company with the proceeds received by the Company used to purchase an equivalent number of LLC Units from such significant stockholder.  The Company’s stock began trading on the New York Stock Exchange on June 25, 2014 under the symbol “ADPT,” and the initial public offering closed on June 30, 2014.
	In connection with the initial public offering, the limited liability company agreement of Adeptus Health LLC was amended and restated to, among other things, modify its capital structure by replacing the different classes of interests previously held by the Adeptus Health LLC owners to a single new class of units called “LLC Units.” In addition, each LLC Unit holder received on a one-for-one basis one share of the Company’s Class B common stock, which entitles the holder to vote on all matters of Adeptus Health Inc. but has no economic rights.  One of the then-existing owners converted a portion of its interest into 4,895,521 shares of the Company’s Class A common stock, which is referred to as the merged entity. The Company and its then-existing owners also entered into an exchange agreement under which they have the right to exchange their LLC Units and shares of Class B common stock for shares of Class A common stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These transactions are collectively referred to as the “Reorganization Transactions.”
	The Company consolidates the financial results of Adeptus Health LLC and its subsidiaries and records non-controlling interest for the economic interest in Adeptus Health LLC held by the non-controlling unit holders. The non-controlling interest ownership percentage as of December 31, 2014 was 52.3%.
	Prior to the initial public offering, the Company borrowed under the Senior Secured Credit Facility (See Note 8 Debt for further information) to fund a dividend of $60.0 million to the then-existing  owners which was paid in connection with the consummation of the initial public offering. The Company used proceeds from the initial public offering to repay indebtedness under the Senior Secured Credit Facility from this borrowing.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation
	The accompanying consolidated balance sheets as of December 31, 2014 and 2013 and the accompanying consolidated statements of operations and cash flows for each of the three years ended December 31, 2014, 2013 and 2012 represent our financial position, results of operations and cash flows as of and for the years then ended.  The consolidated financial statements include the accounts of Adeptus Health Inc. and our wholly owned subsidiaries.  All material intercompany accounts and transactions have been eliminated in consolidation.
	Accounting Policies and Use of Estimates
	The preparation of financial statements in conformity with GAAP requires our management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant accounting policies and estimates include: the useful lives of fixed assets, revenue recognition, allowances for doubtful accounts, leases, reserves for employee health benefit obligations, stock-based compensation, and other contingencies.  Actual results could differ from these estimates.
	Segment and Geographic Information
	The Company’s chief operating decision maker is our Chief Executive Officer, who reviews financial information presented on a company-wide basis. As a result, the Company determined that it has a single reporting segment and operating unit structure.
	All of the Company’s revenue for the years ended December 31, 2014, 2013 and 2012 was in the United States.
	Cash and Cash Equivalents and Concentrations of Risk
	The Company includes all securities with a maturity date of three months or less at date of purchase as cash equivalents. The Company currently has no cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk related to uninsured bank deposits.
	Restricted Cash
	Beginning in October 2013, the Company is required to restrict cash for letters of credit related to the Master Funding and Development Agreement. See Note 11 Commitments and Contingencies for more information. Each letter of credit is issued in an amount equal to approximately 50% of one year's base rent relating to completed facilities. As of December 31, 2014 and 2013, restricted cash was $4.8 million and $0.3 million, respectively.
	Patient Revenue and Accounts Receivable
	Revenues consist primarily of net patient service revenues, which are based on the facilities’ established billing rates less allowances and discounts, principally for patients covered under contractual programs with private insurance companies. Revenue is recognized when services are rendered to patients. Charges for all services provided to insured patients are initially billed and processed by the patients' insurance provider. The Company has agreements with insurance companies that provide for payments to the Company at amounts different from its established rates or as determined by the patient's out of network benefits. Differences between established rates and those set by insurance programs, as well as charity care, employee and prompt pay adjustments, are recorded as adjustments directly to patient service revenue. Fee adjustments of approximately $137.1 million, $62.5 million and $44.5 million were recorded for the years ended December 31, 2014, 2013 and 2012, respectively. Amounts not covered by the insurance companies are then billed to the patients. Estimated uncollectible amounts from insured patients are recorded as bad debt expense in the period the services are provided. Collection of payment for services provided to patients without insurance coverage is done at the time of service.
	With respect to management and contract service revenues, amounts are recognized as services are provided. The Company is party to an agreement with a full-service healthcare hospital facility to provide management services. As compensation for these services, the Company charges the managed entity a management fee based on a fixed percentage of the entity’s net revenue. The Company also holds minority ownership in this entity.
	Patient service revenue before the provision for bad debts by major payor source for the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):
			2014			2013		2012
	Third-party payors, including patient portion		$	237,972		$	113,603	$	79,408
	Self-pay			5,326			1,357		1,569
	Total all payors		$	243,298		$	114,960	$	80,977
	The Company receives payments from third-party payors that have contracts with the Company in Texas and Colorado. As of December 31, 2014, the Company has a contract with Blue Cross Blue Shield of Texas and two MultiPlan arrangements whereby the Company accesses a number of third-party payors at in-network rates. Four major third-party payors accounted for 84.8%,  86.7% and 88.2% of patient service revenue for the years ended December 31, 2014, 2013 and 2012, respectively. These same payors also accounted for 80% and 79% of accounts receivable as of December 31, 2014 and 2013, respectively. The following table sets forth the percentage of patient service revenue earned by major payor source for the years ended December 31, 2014, 2013 and 2012:
		2014		2013		2012
	Payor:
	Blue Cross Blue Shield	27.6	%	28.0	%	29.1	%
	United HealthCare	23.6		26.5		26.0
	Aetna	19.3		21.0		22.1
	Cigna	14.3		11.2		11.0
	Other	15.2		13.3		11.8
		100.0	%	100.0	%	100.0	%
	Accounts receivable are reduced by an allowance for doubtful accounts. In establishing the Company's allowance for doubtful accounts, management considers historical collection experience, the aging of the account, the payor classification, and patient payment patterns. Amounts due directly from patients represent the Company's highest collectability risk. There were not any significant changes in the estimates or assumptions underlying the calculation of the allowance for doubtful accounts for the years ended December 31, 2014 and 2013.
	The Company writes off as bad debt expense uncollectible accounts receivable arising from patient responsibility after all collection efforts have been exhausted and it has been determined such accounts will not be collected. Bad debt write-offs of approximately $24.8 million, $10.1 million and $7.7 million were recorded for the years ended December 31, 2014, 2013 and 2012, respectively.
	The Company treats anyone that is emergent, including patients that may be eligible for Medicare or Medicaid. These services are provided at no charge to the patient. Total charity care was approximately 8.6%,  7.0% and 2.0% of patient service revenue for the years ended December 31, 2014, 2013 and 2012, respectively.
	Advertising Costs
	Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2014, 2013 and 2012, was approximately $5.4 million, $2.1 million and $1.0 million, respectively, and is included as a component of general and administrative expenses within the consolidated statements of operations.
	Medical Supplies Inventory
	Inventory is carried at the lower of cost or market using the first-in, first-out method and consists of a standard set of medical supplies held in stock at all facilities.
	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization computed using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the noncancelable lease term or the estimated useful life of the improvements. When assets are retired, the cost and applicable accumulated depreciation are removed from the respective accounts, and the resulting gain or loss is recognized. Expenditures for normal repairs and maintenance are expensed as incurred. Material expenditures that increase the life of an asset are capitalized and depreciated over the estimated remaining useful life of the asset.  The estimated useful lives of depreciable fixed assets are as follows:
			Estimated useful life
			(in years)
	Computer equipment			3
	Automobiles			5
	Office equipment			5
	Medical equipment			5 to 7
	Leasehold improvement			4 to 10
	Buildings			15 to 20
	Amortization of assets acquired under capital leases is included as a component of depreciation and amortization expense in the accompanying consolidated statements of operations. Amortization is calculated using the straight-line method over the shorter of the useful lives or the term of the underlying lease agreements.
	Impairment of Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset or group of assets might not be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would indicate a potential impairment include a significant decline in the observable market value of an asset or a significant change in the extent or manner in which an asset is used. The impairment review includes a comparison of future projected cash flows generated by the asset or group of assets with its associated net carrying value. If the net carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset exceeds its fair value. The Company recorded long-lived asset impairment charges of $0.3 million for the year ending December 31, 2012, associated with the closing of the former corporate headquarters. There were no impairments recorded for the years ending December 31, 2014 or 2013.
	Goodwill
	In accordance with the FASB ASC 805, Business Combinations, the purchase method of accounting requires that the excess of purchase price paid over the estimated fair value of identifiable tangible and intangible net assets of acquired businesses be recorded as goodwill. In accordance with the provisions of ASC 350, Intangibles—Goodwill and Other, goodwill is tested for impairment annually, and interim impairment tests are performed whenever an event occurs or circumstances change that indicate an impairment has more likely than not occurred. We have one reporting unit and goodwill is evaluated at that level. We evaluate impairment of goodwill by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying value. If it is concluded that this is the case, it is necessary to perform a two‑ step impairment test. The first step involves a comparison of the fair value of a reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, the second step involves a comparison of the implied fair value and the carrying amount of the goodwill of that reporting unit to determine the impairment charge, if necessary. We have established October 31 as the date for our annual impairment review.
	The Company estimates the fair value of its total invested capital using an income and market approach, reduced by interest bearing debt as of the valuation date. These valuations require management to make estimates and assumptions regarding industry economic factors and prospective financial information. There were no goodwill impairment charges recorded for the years ended December 31, 2014, 2013 and 2012.
	Intangible Assets
	Intangible assets are recorded at their estimated fair values as of the date of acquisition. Intangible assets consist of trade and domain names and noncompete agreements. In accordance with ASC 350, Intangibles—Goodwill and Other , the Company reviews the intangible assets with indefinite lives, which include trade and domain names, at least annually for impairment, or more often if triggering events exist. Intangible assets with definite lives are reviewed for impairment if an indicator of impairment exists similar to long-lived assets. An impairment loss is recognized if the carrying amount of an intangible asset is not recoverable and its carrying amount exceeds its fair value. There were no impairment charges recorded on intangible assets for the years ended December 31, 2014, 2013 or 2012. Intangible assets with finite useful lives are amortized over their estimated useful life.
	Fair Value of Financial Instruments
	The carrying amounts of the Company's financial instruments, including cash, receivables, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. At December 31, 2014 and 2013, the carrying value of the Company's long-term debt was based on the current interest rates and approximates its fair value.
	Derivative Instruments and Hedging Activities
	The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. For derivatives not designated as a hedging instrument, changes in the fair value are recorded in net earnings immediately. For derivatives designated in hedging relationships, changes in the fair value are either offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in accumulated other comprehensive income, to the extent the derivative is effective at offsetting the changes in cash flows being hedged until the hedged item affects earnings.
	For the year ended December 31, 2012 and continuing through October 31, 2013, the Company maintained one derivative instrument that it did not designate as a hedge. As a result, changes in the fair value were recorded in earnings for this period. Beginning in November 2013, the Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or years during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.
	The Company discontinues hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised or the cash flow hedge is redesignated because a forecasted transaction is not probable of occurring.
	In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship.
	Lease Accounting
	The Company determines whether to account for its facility leases as operating or capital leases depending on the underlying terms of the lease agreement. This determination of classification is complex and requires significant judgment relating to certain information including the estimated fair value and remaining economic life of the facilities, the Company's cost of funds, minimum lease payments and other lease terms. The lease rates under the Company's lease agreements are subject to certain conditional escalation clauses that are recognized when probable or incurred and are based on changes in the consumer price index or certain operational performance measures. As of December 31, 2014, the Company leased 54 facilities, 53 of which the Company classified as operating leases and one of which the Company classified as a capital lease.
	Income Taxes
We provide for income taxes using the asset and liability method. This approach recognizes the amount of federal, state and local taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.
A valuation allowance is required when it is more-likely-than-not that some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income.
We file a consolidated federal income tax return. State income tax returns are filed on a separate, combined or consolidated basis in accordance with relevant state laws and regulations. LPs, LLPs, LLCs and other pass-through entities that we consolidate file separate federal and state income tax returns. We include the allocable portion of each pass-through entity’s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.
The (benefit) provision for income taxes totaled $(1.3) million, $0.7 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012, respectively. The Company's estimate of the potential outcome of any uncertain tax positions is subject to management's assessment of relevant risks, facts, and circumstances existing at that time. The Company uses a more likely than not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
To the extent that the Company's assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax related interest and penalties as a component of the provision for income tax and operating expenses, respectively, if applicable. The Company has not recognized any uncertain tax positions.
Deferred Rent
The Company records rent expense for operating leases on a straight-line basis over the life of the related leases. The Company has certain facility and equipment leases that allow for leasehold improvements allowances, free rent, and escalating rental payments. Straight-line expenses that are greater than the actual amount paid are recorded as deferred rent and amortized over the life of the lease.
Investment in Unconsolidated Joint Venture
Investments in unconsolidated companies in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. The Company has one such investment with an ownership interest of 49.9%.
This investment is included as investment in unconsolidated joint venture in the accompanying consolidated balance sheets.
Equity in net loss of unconsolidated joint venture consists of the Company’s share of the losses generated from its noncontrolling equity investment in one full-service healthcare hospital facility. Because these operations are central to the Company’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of operations. The Company has contracts to manage these facilities, which results in the Company having an active role in the operations of these facilities and devoting a significant portion of its corporate resources to the fulfillment of these management responsibilities.
Recent Accounting Pronouncements
In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.

PROPERTY_AND_EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT
PROPERTY AND EQUIPMENT	NOTE 3—PROPERTY AND EQUIPMENT
	Property and equipment consisted of the following, as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Leasehold improvements	$	77,354	$	37,626
	Computer equipment		3,700		1,583
	Medical equipment		4,213		2,970
	Office equipment		4,307		760
	Automobiles		243		243
	Land		8,276		2,430
	Construction in progress		8,835		17,788
	Buildings		4,667		4,551
			111,595		67,951
	Less accumulated depreciation		-17,703		-5,864
	Property and equipment, net	$	93,892	$	62,087
	Assets under capital leases totaled approximately $4.2 million and $3.9 million as of December 31, 2014 and 2013, respectively, and were included within the buildings component of net property and equipment. Accumulated depreciation associated with these capital lease assets totaled approximately $0.3 million and $23,000 as of December 31, 2014 and 2013, respectively.

INVESTMENT_IN_UNCONSOLIDATED_J

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT
INVESTMENT IN UNCONSOLIDATED JOINT VENTURE	NOTE 4—INVESTMENT IN UNCONSOLIDATED JOINT VENTURE
	On October 22, 2014, the Company announced its expansion into Arizona through a joint venture with Dignity Health, one of the nation’s largest health systems. The new partnership has started with Dignity Health Arizona General Hospital, a full-service healthcare hospital facility in Phoenix, Arizona, and includes providing for additional access to emergency medical care in Phoenix. As of December 31, 2014, this facility was in its training and certification phase until such time as it received CMS certification from the Joint Commission. The joint venture received CMS certification on January 30, 2015.  Dignity Health Arizona General Hospital is a full-service healthcare hospital facility, licensed by the state as a general hospital. Spanning 39,000 square-feet, the hospital has 16 inpatient rooms, two operating rooms for inpatient and outpatient surgical procedures, an emergency department, a high-complexity laboratory and a full radiology suite. Patients have full access to the Dignity Health area facilities and physicians, and the hospital will provide Phoenix-area residents with 24/7 access to emergency medical care.
	The Company accounts for this under the equity method of accounting as an investment in unconsolidated joint venture, as the Company’s level of influence is significant but does not reach the threshold of controlling the entity.
	Summarized unaudited financial information for the Company’s equity method investee is as follows (in thousands):
		Year ended
		December 31,
		2014
	Net patient service revenue	$	247
	Operating expenses:
	Salaries, wages and benefits		880
	General and administrative		469
	Other operating expenses		688
	Depreciation and amortization		12
	Total operating expenses		2,049
	Loss from operations		-1,802
	Other (expense) income:
	Interest expense		-1
	Total other (expense)		-1
	Net loss	$	-1,803
	Balance sheet information (as of December 31, 2014):
	Current assets	$	1
	Noncurrent assets		5
	Current liabilities		2
	Noncurrent liabilities		0.1

GOODWILL_AND_OTHER_INTANGIBLE_

GOODWILL AND OTHER INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2014
GOODWILL AND OTHER INTANGIBLE ASSETS
GOODWILL AND OTHER INTANGIBLE ASSETS	NOTE 5—GOODWILL AND OTHER INTANGIBLE ASSETS
	The following table summarizes the change in goodwill during the years ended December 31, 2014 and 2013 (in thousands):
		2014		2013
	Balance at beginning of year	$	61,009		61,009
	Adjustments		—		—
	Balance at end of year	$	61,009	$	61,009
	The following table summarizes the change in intangible assets during the years ended December 31, 2014 and 2013 (in thousands):
		Noncompete		Trade		Domain
		Agreements		Names		Names		Total
	Balance at December 31, 2012	$	6,675	$	9,300	$	7,600	$	23,575
	Additions		—		—		—		—
	Amortization		-1,780		—		—		-1,780
	Balance at December 31, 2013	$	4,895	$	9,300	$	7,600	$	21,795
	Additions		—		—		—		—
	Amortization		-1,780		—		—		-1,780
	Balance at December 31, 2014	$	3,115	$	9,300	$	7,600	$	20,015
	As of December 31, 2014, the following table sets forth the estimated amortization of the noncompete agreements for the years ending December 31 (in thousands):
	2015	$	1,780
	2016		1,335

DERIVATIVE_INSTRUMENTS_AND_HED

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	12 Months Ended
	Dec. 31, 2014
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
	NOTE 6—DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
	The Company uses interest-rate-related derivative instruments to manage its exposure related to changes in interest rates on its variable-rate debt instruments. The Company does not enter into derivative instruments for any purpose other than cash flow hedging. The Company does not speculate using derivative instruments.
	By using derivative financial instruments to hedge exposures to changes in interest rates, the Company exposes itself to credit risk and market risk. Credit risk is the failure of the counterparty to perform under the terms of the derivative contract. When the fair value of a derivative contract is positive, the counterparty owes the Company, which creates credit risk for the Company. When the fair value of a derivative contract is negative, the Company owes the counterparty, and therefore, the Company is not exposed to the counterparty's credit risk in those circumstances. The Company minimizes counterparty credit risk in derivative instruments by entering into transactions with high-quality counterparties whose credit rating is higher than Aa. The derivative instruments entered into by the Company do not contain credit-risk-related contingent features.
	Market risk is the adverse effect on the value of a derivative instrument that results from a change in interest rates, currency exchange rates, or commodity prices. The market risk associated with interest-rate contracts is managed by establishing and monitoring parameters that limit the types and degree of market risk that may be undertaken.
	The Company assesses interest rate risk by continually identifying and monitoring changes in interest rate exposures that may adversely impact expected future cash flows and by evaluating hedging opportunities. The Company maintains risk management control systems to monitor interest rate risk attributable to both the Company's outstanding or forecasted debt obligations as well as the Company's offsetting hedge positions. The risk management control systems involve the use of analytical techniques, including cash flow sensitivity analysis, to estimate the expected impact of changes in interest rates on the Company's future cash flows.
	Changes in the fair value of interest rate swaps and cap agreements designated as hedging instruments that effectively offset the variability of cash flows associated with variable-rate, long-term debt obligations are reported in accumulated other comprehensive income. These amounts subsequently are reclassified into interest expense as a yield adjustment of the hedged interest payments in the same period in which the related interest affects earnings.
	In May 2012, the Company entered into a forward interest rate swap agreement with a notional amount of $24.0 million to manage exposure to changes in interest rates associated with its variable interest rate debt. This agreement had the economic effect of modifying the LIBOR variable component of the Company's interest rate on an equivalent amount of the Company's Term Loan to a fixed rate of 1.20%. This swap agreement was not designated by the Company as a hedge as of December 31, 2013. The Company did not utilize the swap agreement until April 30, 2013. The Company recognized a loss of approximately $0.1 million for the year ended December 31, 2013 and a gain of approximately $0.5 million for the year ended December 31, 2012 on the change in fair value of the swap agreement, which is included as a component of other (expense) income within the consolidated statements of operations.
	As of December 31, 2014, the Company maintained one interest rate cap agreement with notional amount totaling $37.5 million. This agreement has the economic effect of capping the LIBOR variable component of the Company's interest rate at a maximum of 3.00% on an equivalent amount of the Company's Term Loan debt. The cap agreement was entered into in November 2013 at a cost of $0.09 million and expires on November 30, 2016. This cap agreement is designated as a cash flow hedge and, as a result, changes in the fair values of this cap agreement are reported in other comprehensive income. As of December 31, 2014, approximately $74,000 of deferred losses on derivative instruments are included in other comprehensive income. The cap agreement does not contain credit-risk contingent features.
	The following table summarizes the Company's derivative instruments as of December 31, 2014 and 2013 (in thousands):
			2014		2013
		Balance Sheet Location	Fair Value		Fair Value
	Derivative designated as hedging instruments
	Interest rate contracts	Other long-term assets	$	19	$	92

ACCOUNTS_PAYABLE_AND_ACCRUED_E

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2014
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 7—ACCOUNTS PAYABLE AND ACCRUED EXPENSES
	Accounts payable and accrued expenses consisted of the following as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Accounts payable	$	14,133	$	9,405
	Accrued expenses		4,431		1,267
	Accrued tax distribution to LLC Unit holders		4,246		3,772
	Other		2,610		763
	Total accounts payable and accrued expenses	$	25,420	$	15,207

DEBT

DEBT	12 Months Ended
	Dec. 31, 2014
DEBT
DEBT	NOTE 8—DEBT
	The components of debt consisted of the following as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Term loan	$	75,000	$	75,000
	Delayed draw term loan		25,000		—
	Revolving credit		5,500
	Other financing agreements		1,298		504
			106,798		75,504
	Less current maturities		-1,816		-504
		$	104,982	$	75,000
	On October 31, 2013, the Company entered into a Senior Secured Credit Facility (the “Facility”) for a $75.0 million term loan which matures on October 31, 2018. The Facility includes an additional $165.0 million delayed draw term loan commitment, which, if unused, expires eighteen months after the closing date, and a $10.0 million revolving commitment that matures on October 31, 2018. All of the Company's assets are pledged as collateral under the Facility. The borrowing under the Facility is used by the Company to provide financing for working capital, capital expenditures and for new facility expansion and replaced the Company's existing credit facility.
	On March 31, 2014, the Company amended the Facility to, among other things, increase the maximum aggregate amount permitted to be funded by Medical Properties Trust (“MPT”) under the Master Funding and Development Agreement (the “MPT Agreement”) to $255.0 million.
	On June 11, 2014, the Company entered into a second amendment to the Facility to, among other things, provide for a borrowing under the delayed draw term loan in an aggregate principal amount of up to $75.0 million, up to $60.0 million in principal amount of which will be used to make specified distributions and up to $10.0 million in principal amount of which will be used to repay certain revolving loans.  On June 11, 2014, the Company drew $75.0 million and made the $60.0 million dividend distribution on June 24, 2014.
	Borrowings under the Facility bear interest, at our option, at a rate equal to an applicable margin over (a) a base rate determined by reference to the highest of (1) the prime rate, (2) the federal funds effective rate plus 0.50% and (3) LIBOR of at least 1%, or (b) LIBOR for the applicable interest period. The margin for the Facility is 6.50% in the case of base rate loans and 7.50% in the case of LIBOR loans. The Facility includes an unused line fee of 0.50% per annum on the revolving commitment and delayed draw term loan commitment, a draw fee of 1.0% of the principal amount of each borrowing on the delayed draw term loan and an annual Agency fee of $0.1 million. At December 31, 2014 and 2013, the Company had $80.2 million and $165.0 million available under the delayed draw term commitment, respectively. At December 31, 2014 and 2013, the Company had approximately $4.0 million and $9.5 million available under the revolving commitment, respectively.
	The original principal amount of the term loan will be repaid in consecutive quarterly installments of $0.5 million on the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2015 and escalating to $0.9 million for each fiscal quarter ending after December 31, 2016. The delayed draw term loans will be repaid in consecutive quarterly installments in an amount based on the repayment calculation contained in the Facility on the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2015. The aggregate principal amount of all revolving loans outstanding are due on the maturity date, October 31, 2018.
	The Facility contains certain affirmative covenants, negative covenants, and financial covenants which are measured on a quarterly basis. As of December 31, 2014, the Company was in compliance with all covenant requirements.
	In 2014, the Company entered into finance agreements totaling approximately $1.9 million to finance the renewal of certain insurance policies. The finance agreements have fixed interest rates ranging between 2.49% and 3.25% with principal being repaid over 9 to 11 months. In October 2013, the Company renewed certain insurance policies and entered into a finance agreement totaling approximately $0.8 million. The finance agreement has a fixed interest rate of 1.93% with principal being repaid over 9 months. In October 2012, the Company renewed certain insurance policies and entered into a finance agreement totaling approximately $0.4 million. The finance agreement has a fixed interest rate of 3.48% with principal being repaid over 11 months.
	Future Maturities
	Scheduled future aggregate maturities of principal of long-term debt are as follows: (in thousands):
	Years ending December 31,	Amount
	2015	$	1,816
	2016		2,763
	2017		5,000
	2018		97,219
		$	106,798

TRANSACTIONS_WITH_RELATED_PART

TRANSACTIONS WITH RELATED PARTIES	12 Months Ended
	Dec. 31, 2014
TRANSACTIONS WITH RELATED PARTIES
TRANSACTIONS WITH RELATED PARTIES	NOTE 9—TRANSACTIONS WITH RELATED PARTIES
	The Company made payments to a significant shareholder of the Company for management services and reimbursement of certain expenses related to an advisory services agreement. The total amount paid to this related party was approximately $0.8 million,  $0.6 million and $0.6 million for the years ended December 31, 2014, 2013 and 2012, respectively.  In connection with the consummation of the initial public offering, the advisory services agreement was terminated and the Company paid a $2.0 million termination fee which was paid in July 2014.
	The Company made payments for contractor services to various related-party vendors, which totaled approximately $0.06 million, $0.06 million and $0.1 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	We entered into a license and master services agreement with IO Phoenix One, LLC, or IO, an affiliate of a significant shareholder on November 22, 2013, pursuant to which IO stores and maintains our data centers and modules at its Phoenix, Arizona location. We pay approximately $4,000 per month in license fees with an initial term of 36 months. The total amount payable under the agreement is approximately $148,000, with payments beginning on February 15, 2014.

EMPLOYEE_BENEFIT_PLANS

EMPLOYEE BENEFIT PLANS	12 Months Ended
	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
EMPLOYEE BENEFIT PLANS	NOTE 10—EMPLOYEE BENEFIT PLANS
	The Company provides a 401(k) savings plan to all employees who have met certain eligibility requirements, including performing one month of service with the Company. The 401(k) plan permits matching and discretionary employer contributions. During the years ended December 31, 2014 and 2013, the Company contributed approximately $0.5 million and $0.3 million to the 401(k) Plan for 2013 and 2012 matching contributions, respectively. The board of directors approved a contribution of $0.9 million for the year ended December 31, 2014, which will be paid during 2015.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 11—COMMITMENTS AND CONTINGENCIES
	Litigation and Asserted Claims
	The Company is a defendant in various legal proceedings arising in the ordinary course of business. While, management believes the outcome of pending litigation and claims will not have a material adverse effect on the Company's consolidated financial condition, operations, or cash flows, litigation is subject to inherent uncertainties.
	Insurance Arrangements
	The Company is self-insured for employee health benefits. Accruals for losses are provided based upon claims experience and actuarial assumptions, including provisions for incurred but not reported losses. At December 31, 2014 and 2013, the Company has an accrual of approximately $0.7 million and $0.7 million, respectively for incurred but not reported claims, which is included in accrued compensation within the consolidated balance sheets.
	The Company is insured for worker's compensation claims up to $1.0 million per accident and per employee with a policy limit of $1.0 million. The Company submits periodic payments to its insurance broker based upon estimated payroll. Worker's compensation expense for the years ended December 31, 2014, 2013 and 2012 was approximately $0.3 million, $0.07 million and $ 0.03 million, respectively. The Company is insured for professional liability claims up to $1.0 million per incident and $3.0 million per facility with an aggregate policy limit of $20.0 million.
	Leases
	The Company leases certain medical facilities and equipment under various noncancelable operating leases. In June 2013, the Company entered into the MPT Agreement with MPT to fund future facilities. The lessor to the MPT Agreement will acquire parcels of land, fund the ground-up construction of new freestanding emergency room facilities and lease the facilities to the Company upon completion of construction. Under the terms of the agreement, the lessor is to fund all hard and soft costs, including the project purchase price, closing costs and pursuit costs for the assets relating to the construction of up to twenty-five facilities with a maximum aggregate funding of $100.0 million. Each completed project will be leased for an initial term of 15 years, with three 5-year renewal options. The Company follows the guidance in ASC 840, Leases, and ASC 810, Consolidation, in evaluating the lease as a build-to-suit lease transaction to determine whether the Company would be considered the accounting owner of the facilities during the construction period.
	In July 2014, the Company entered into an additional Master Funding and Development Agreement with MPT to fund future facilities. This agreement is separate from and in addition to the Company’s existing MPT Agreement. The new agreement allows for an additional maximum aggregate funding of $150.0 million. All other material terms remain consistent with the existing MPT Agreement.
	The Company leases approximately 80,000 square feet for its corporate headquarters. Lease expense associated with this lease was $1.4 million, $0.7 million and $0.1 million for the years ended December 31, 2014, 2013 and 2012, respectively.
	Future minimum lease payments required under noncancelable operating leases and future minimum, capital lease payments as of December 31, 2014 were as follows (in thousands):
		Capital		Operating
	Years ending December 31,	leases		leases
	2015	$	522	$	26,318
	2016		533		25,249
	2017		544		22,993
	2018		554		18,984
	2019		565		15,899
	Thereafter		5,512		139,184
	Total future minimum lease payments	$	8,230	$	248,627
	Less: Amounts representing interest		-4,093
	Present value of minimum lease payments		4,137
	Current portion of capital lease obligations		81
	Long-term portion of capital lease payments	$	4,056
	Rent expense totaled approximately $15.2 million, $4.5 million and $2.1 million for the years ended December 31, 2014, 2013 and 2012, respectively and is included as a component of other operating expenses within the Consolidated Statements of Operations.
	In January 2013, the Company entered into a termination agreement with the landlord of the leased facility in Georgetown, Texas. Under the termination agreement, the landlord and the Company mutually released the other from any further obligations under the lease and any liability, cause of action, claim, or loss arising out of or connected with the lease. In accordance with the termination agreement, the Company paid the landlord a lease termination fee of $0.2 million.

SUPPLEMENTAL_CASH_FLOW_INFORMA

SUPPLEMENTAL CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	NOTE 12— SUPPLEMENTAL CASH FLOW INFORMATION
	Supplemental cash flow information and supplemental noncash activities consisted of the following for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		2014		2013		2012
	Supplemental cash flow information:
	Interest paid	$	9,294	$	2,486	$	1,091
	Franchise taxes paid		680		530		296
	Supplemental noncash activities:
	Acquisition of property and equipment in accounts payable and accrued expenses	$	2,239	$	467	$	2,341
	Assets acquired through capital lease		287		3,911		—
	Note payable for other financing agreements		2,056		757		390
	Accrual of owner distributions		474		1,735		2,042

STOCK_BASED_COMPENSATION

STOCK BASED COMPENSATION	12 Months Ended
	Dec. 31, 2014
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION
	NOTE 13—STOCK BASED COMPENSATION
	In connection with the initial public offering, the Company’s Board of Directors adopted the Adeptus Health Inc. 2014 Omnibus Incentive Plan (the “Omnibus Incentive Plan”). The Omnibus Incentive Plan provides for the granting of stock options, restricted stock and other stock-based or performance-based awards to directors, officers, employees, consultants and advisors of the Company and its affiliates. The total number of shares of Class A common stock that may be issued under the Omnibus Incentive Plan is 1,033,500.  On June 24, 2014, the Company granted 11,934 restricted Class A shares to its non-employee directors under the Omnibus Incentive Plan, representing the prorated amount of the directors’ annual equity award for fiscal 2014. These restricted shares will vest on January 1, 2015. In July 2014, the Company granted to certain employees 35,856 restricted Class A shares, which vest over 4 years. The fair value of each restricted share award is based on the closing common stock price on the date of grant. The weighted average price of restricted shares granted in 2014 is $24.33 per share. Compensation expense for time-based restricted share awards is recognized over the vesting period on a straight-line basis, adjusted for estimated forfeitures. All outstanding restricted Class A shares were unvested as of December 31, 2014. As of December 31, 2014, there was $0.3 million of unrecognized compensation cost related to time-based restricted share awards. That cost is expected to be recognized over a weighted average period of 2 years. The aggregate intrinsic value of time-based share awards was $0.9 million as of December 31, 2014.
	The Company also has one legacy equity-compensation plan, under which it has issued agreements awarding incentive units (restricted units) in the Company to certain employees and non-employee directors. In conjunction with the Reorganization Transactions, these restricted units were replaced with LLC Units with consistent restrictive terms. The restricted units are subject to such conditions as continued employment, passage of time and/or satisfaction of performance criteria as specified in the agreements. The restricted units vest over 3 to 4 years from the date of grant. The Company used a waterfall calculation, based on the capital structure and payout of each class of debt and equity, and a present value pricing model less marketability discount to determine the fair values of the restricted units. The assumptions used in the price simulation model for units granted during 2013 include risk-free interest rates of 0.93%, volatility of 25.0% and a dividend rate of 0%. The weighted average fair value of incentive units granted during the year ended December 31, 2013 was $1,262 and $384 for the time-based and performance based units, respectively. The assumptions used for the 2012 incentive units included a risk-free interest rate of 0.72%, volatility of 30.0% and a dividend yield of 0%.  The weighted average fair value of incentive units granted during 2012 was $204 and $37 for the time-based and performance based units, respectively. The Company did not issue any incentive units under the legacy plan during the year ended December 31, 2014.
	The Company recorded compensation expense of $1.0 million, $0.6 million, and $0.3 million, adjusted for forfeitures, during the years ended December 31, 2014, 2013 and 2012, respectively, related to restricted units with time-based vesting schedules. Compensation expense for the value of the portion of the time-based restricted unit that is ultimately expected to vest is recognized using a straight-line method over the vesting period, adjusted for forfeitures. No compensation expense was recorded during the years ended December 31, 2014 and 2013 related to restricted units with performance-based vesting criteria. If, and when, the Company determines it is probable that the performance condition will be achieved, compensation expense will be recognized cumulatively in such period. Total unrecognized compensation expense related to performance based restricted units was $0.1 million as of December 31, 2014

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14— INCOME TAXES
	The components of our (benefit) provision for income taxes were as follows (in thousands):
			2014		2013		2012
	Current:
	Federal	$	-	$	-	$	-
	State		821		720		467
	Total Current Taxes		821		720		467
	Deferred:
	Federal		-2,123		-		-
	State		-24		-		-
	Total Deferred Taxes		-2,147		-		-
	Total Income tax (benefit) provision	$	-1,326	$	720	$	467
	The reconciliation of our income tax (benefit) expense computed at the U.S. federal statutory tax rate to the actual income tax (benefit) expense is as follows (in thousands):
			2014		2013		2012
	Expense derived by applying the Federal Income tax rate to income (loss) before taxes	$	-6,509	$	-792	$	1,284
	Tax applicable to pass-through entities		4,631		792		-1,284
	State Income Tax, net of federal benefit		534		-		-
	Investment in Partnership (Nondeductible expenses)		18		-		-
		$	-1,326	$	-	$	-
	Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.  Significant components of our deferred tax assets and liabilities are as follows (in thousands):
			2014		2013		2012
	Deferred Tax Assets
	TRA Liability	$	8,125	$	-	$	-
	Investment in Partnership		20,940		-		-
	Net Operating Loss Carryforwards		4,957		-		-
	State Net Operating Loss Carryforwards		62		-		-
	Total Deferred Tax Assets	$	34,084	$	-	$	-
	Prior to the Reorganization, we were not a federal taxpayer.  Due to the timing of the Company’s initial public offering, taxes were calculated based on activity from June 25, 2014 through the end of the period. The Company’s effective tax rate for the period subsequent to June 25, 2014 differs from the statutory rates due primarily to state taxes that are not based on pre-tax income/(loss) but on gross margin resulting in state tax expense even in periods of pretax losses.
	Our management evaluates the realizability of the deferred tax assets and determines whether it is more likely than not that the deferred tax assets are realizable. We consider whether a valuation allowance is needed on our deferred tax assets by evaluating all positive and negative evidence relative to our ability to recover deferred tax assets, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies and recent financial operations. During 2014, we were able to conclude that given our performance, the forecast of future income, the realization of our deferred tax asset was more likely than not and did not record a valuation allowance for the period. This determination is based on an estimated forecast of future taxable income which includes many judgments and assumptions. Accordingly, it is at least reasonably possible for future changes in one or more assumptions may lead to a change in judgment regarding the necessity of a valuation allowance required in future periods.
	Our largest deferred tax asset is related to our investment in partnership of $21.0 million. This deferred tax asset is a result of the differences between the book and tax basis in Adeptus Health LLC, which is the partnership that operates our facilities.
	A second component of the deferred tax asset is related to the Tax Receivable Agreement (noted below) liability of $8.1 million.  As the Company becomes profitable, the deferred tax asset related to this liability will be reduced.
	The final component of the deferred tax asset is the federal net operating loss carryforwards of $5.0 million. The federal net operating losses will begin to expire in 2034.  The net operating loss carryforward is primarily related to depreciation and amortization deductions as well as change in accounting method for tax purposes related to bad debts.
	A cumulative change in ownership among material shareholders, as defined in Section 382 of the Internal Revenue Code, during a three-year period may limit the utilization of the federal net operating loss carryforwards. At this time, the Company is not subject to the Section 382 limitation; however the Company may be subject to this limitation depending on the extent and timing of change in ownership in the future.
	Uncertain Tax Positions
	At December 31, 2014, the Company has not identified or accrued for any uncertain tax positions. Our policy is to include interest and penalties related to uncertain tax positions, and as of December 31, 2014, there were no accrued interest and penalties. We file tax returns in the U.S. federal jurisdiction and state jurisdictions where we have facilities and operations. We are not currently under audit for federal or any state jurisdictions.
	Tax Receivable Agreement
	Upon the consummation of the Company’s initial public offering, the Company entered into a tax receivable agreement with the LLC Unit holders after the closing of the offering that provides for the payment from time to time by the Company to the LLC Unit holders of 85% of the amount of the benefits, if any, that the Company is deemed to realize as a result of increases in tax basis and certain other tax benefits related to exchanges of LLC Units pursuant to the exchange agreement, including tax benefits attributable to payments under the tax receivable agreement.  These payment obligations are obligations of the Company.  For purposes of the tax receivable agreement, the benefit deemed realized by the Company was computed by comparing its actual income tax liability (calculated with certain assumptions) to the amount of such taxes that the Company would have been required to pay had there been no increase to the tax basis of the assets of Adeptus Health LLC as a result of the exchanges and had the Company not entered into the tax receivable agreement. The step-up in basis will depend on the fair value of the LLC Units at conversion.
	As of December 31, 2014, the Company has recorded an estimated payable pursuant to the tax receivable agreement of $30.0 million related to certain transactions in conjunction with the initial public offering that are expected to give rise to certain tax benefits in the future.

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
NET (LOSS) PER SHARE	NOTE 15— NET LOSS PER SHARE
	Prior to the consummation of the Company’s initial public offering, the Company did not have outstanding common stock. However, in conjunction with the closing of the initial public offering, an existing owner exchanged their LLC Units for shares of the Company’s Class A common stock.  The Company has assumed that 4,895,521 shares of Class A common stock were outstanding during the entire periods subsequent to the Company’s initial public offering for purposes of calculating net loss per share. Additional shares included in the calculation include 4,900,000 Class A common shares issued to the public, 11,934 restricted shares of Class A common stock that were issued to our directors and 38,856 restricted shares of Class A common stock that were issued to certain employees.
	The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2014, 2013 and 2012 (in thousands, except share and per share data):
		2014		2013		2012
	Numerator
	Net loss attributable to Adeptus Health Inc.	$	-3,351	$	—	$	—
	Denominator:
	Class A common share-weighted average shares		9,845,016		—		—
	Effect of dilutive securities:
	Restricted shares		—		—		—
	Denominator for diluted net loss per Class A common share-weighted average shares		9,845,016		—		—
	Net loss attributable to Adeptus Health Inc. per Class A common share - Basic	$	-0.34	$	—	$	—
	Net loss attributable to Adeptus Health Inc. per Class A common share - Diluted	$	-0.34	$	—	$	—
	Earnings (loss) per share information is not applicable for reporting periods prior to the initial public offering. The shares of Class B common stock do not share in the earnings or losses of Adeptus Health Inc. and are therefore not participating securities. Accordingly, basic and diluted net loss per share of Class B common stock has not been presented.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 16—SUBSEQUENT EVENTS
	The Company has evaluated subsequent events from the balance sheet date through the date at which the consolidated financial statements were available to be issued, and determined that there were no other items to disclose.

SELECTED_QUARTERLY_FINANCIAL_D

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
SELECTED QUARTERLY FINANCIAL INFORMATION (UNAUDITED)	NOTE 17—SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
	The following table presents certain unaudited quarterly statement of operations data for the years ended December 31, 2014 and 2013. Results of operations for any particular quarter are not necessarily indicative of results of operations for a full year or predictive of future periods.
		Three months ended
		December 31,		September 30,		June 30,		March 31,		December 31,		September 30,		June 30,		March 31,
		2014		2014		2014		2014		2013		2013		2013		2013
		(in thousands, except per share data)
	Patient service revenue	$	80,290	$	66,533	$	51,946	$	44,529	$	38,885	$	25,947	$	26,831	$	23,297
	Provision for bad debt		-10,234		-8,934		-7,708		-5,748		-5,173		-2,310		-2,333		-2,261
	Net patient service revenue		70,056		57,599		44,238		38,781		33,712		23,637		24,498		21,036
	Management and contract services revenue		20		—		—		—		—		—		—		—
	Total net operating revenue		70,076		57,599		44,238		38,781		33,712		23,637		24,498		21,036
	(Loss) income from operations		-139		-1,079		-5,072		-341		504		-599		1,401		-415
	Net (loss) income		-1,477		-3,598		-9,429		-2,767		-1,974		-1,511		1,336		-835
	Less: Net (loss) income attributable to non-controlling interest		-1,739		-2,001		-7,413		-2,767		-1,974		-1,511		1,336		-835
	Net income (loss) attributable to Adeptus Health Inc.	$	262	$	-1,597	$	-2,016	$	—	$	—	$	—	$	—	$	—
	Net loss per share of Class A common stock:
	Basic and Diluted	$	0.03	$	-0.16	$	-0.21	$	—	$	—	$	—	$	—	$	—

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation	Basis of Presentation
	The accompanying consolidated balance sheets as of December 31, 2014 and 2013 and the accompanying consolidated statements of operations and cash flows for each of the three years ended December 31, 2014, 2013 and 2012 represent our financial position, results of operations and cash flows as of and for the years then ended.  The consolidated financial statements include the accounts of Adeptus Health Inc. and our wholly owned subsidiaries.  All material intercompany accounts and transactions have been eliminated in consolidation.
Accounting Policies and Use of Estimates
	Accounting Policies and Use of Estimates
	The preparation of financial statements in conformity with GAAP requires our management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant accounting policies and estimates include: the useful lives of fixed assets, revenue recognition, allowances for doubtful accounts, leases, reserves for employee health benefit obligations, stock-based compensation, and other contingencies.  Actual results could differ from these estimates.
Segment and Geographic Information	Segment and Geographic Information
	The Company’s chief operating decision maker is our Chief Executive Officer, who reviews financial information presented on a company-wide basis. As a result, the Company determined that it has a single reporting segment and operating unit structure.
	All of the Company’s revenue for the years ended December 31, 2014, 2013 and 2012 was in the United States.
Cash and Cash Equivalents and Concentrations of Risk	Cash and Cash Equivalents and Concentrations of Risk
	The Company includes all securities with a maturity date of three months or less at date of purchase as cash equivalents. The Company currently has no cash equivalents. The Company maintains its cash in bank deposit accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts and does not believe it is exposed to any significant risk related to uninsured bank deposits.
Restricted Cash	Restricted Cash
	Beginning in October 2013, the Company is required to restrict cash for letters of credit related to the Master Funding and Development Agreement. See Note 11 Commitments and Contingencies for more information. Each letter of credit is issued in an amount equal to approximately 50% of one year's base rent relating to completed facilities. As of December 31, 2014 and 2013, restricted cash was $4.8 million and $0.3 million, respectively.
Patient Revenue and Accounts Receivable	Patient Revenue and Accounts Receivable
	Revenues consist primarily of net patient service revenues, which are based on the facilities’ established billing rates less allowances and discounts, principally for patients covered under contractual programs with private insurance companies. Revenue is recognized when services are rendered to patients. Charges for all services provided to insured patients are initially billed and processed by the patients' insurance provider. The Company has agreements with insurance companies that provide for payments to the Company at amounts different from its established rates or as determined by the patient's out of network benefits. Differences between established rates and those set by insurance programs, as well as charity care, employee and prompt pay adjustments, are recorded as adjustments directly to patient service revenue. Fee adjustments of approximately $137.1 million, $62.5 million and $44.5 million were recorded for the years ended December 31, 2014, 2013 and 2012, respectively. Amounts not covered by the insurance companies are then billed to the patients. Estimated uncollectible amounts from insured patients are recorded as bad debt expense in the period the services are provided. Collection of payment for services provided to patients without insurance coverage is done at the time of service.
	With respect to management and contract service revenues, amounts are recognized as services are provided. The Company is party to an agreement with a full-service healthcare hospital facility to provide management services. As compensation for these services, the Company charges the managed entity a management fee based on a fixed percentage of the entity’s net revenue. The Company also holds minority ownership in this entity.
	Patient service revenue before the provision for bad debts by major payor source for the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):
			2014			2013		2012
	Third-party payors, including patient portion		$	237,972		$	113,603	$	79,408
	Self-pay			5,326			1,357		1,569
	Total all payors		$	243,298		$	114,960	$	80,977
	The Company receives payments from third-party payors that have contracts with the Company in Texas and Colorado. As of December 31, 2014, the Company has a contract with Blue Cross Blue Shield of Texas and two MultiPlan arrangements whereby the Company accesses a number of third-party payors at in-network rates. Four major third-party payors accounted for 84.8%,  86.7% and 88.2% of patient service revenue for the years ended December 31, 2014, 2013 and 2012, respectively. These same payors also accounted for 80% and 79% of accounts receivable as of December 31, 2014 and 2013, respectively. The following table sets forth the percentage of patient service revenue earned by major payor source for the years ended December 31, 2014, 2013 and 2012:
		2014		2013		2012
	Payor:
	Blue Cross Blue Shield	27.6	%	28.0	%	29.1	%
	United HealthCare	23.6		26.5		26.0
	Aetna	19.3		21.0		22.1
	Cigna	14.3		11.2		11.0
	Other	15.2		13.3		11.8
		100.0	%	100.0	%	100.0	%
	Accounts receivable are reduced by an allowance for doubtful accounts. In establishing the Company's allowance for doubtful accounts, management considers historical collection experience, the aging of the account, the payor classification, and patient payment patterns. Amounts due directly from patients represent the Company's highest collectability risk. There were not any significant changes in the estimates or assumptions underlying the calculation of the allowance for doubtful accounts for the years ended December 31, 2014 and 2013.
	The Company writes off as bad debt expense uncollectible accounts receivable arising from patient responsibility after all collection efforts have been exhausted and it has been determined such accounts will not be collected. Bad debt write-offs of approximately $24.8 million, $10.1 million and $7.7 million were recorded for the years ended December 31, 2014, 2013 and 2012, respectively.
	The Company treats anyone that is emergent, including patients that may be eligible for Medicare or Medicaid. These services are provided at no charge to the patient. Total charity care was approximately 8.6%,  7.0% and 2.0% of patient service revenue for the years ended December 31, 2014, 2013 and 2012, respectively.
Advertising Costs	Advertising Costs
	Advertising costs are expensed as incurred. Advertising expense for the years ended December 31, 2014, 2013 and 2012, was approximately $5.4 million, $2.1 million and $1.0 million, respectively, and is included as a component of general and administrative expenses within the consolidated statements of operations.
Medical Supplies Inventory	Medical Supplies Inventory
	Inventory is carried at the lower of cost or market using the first-in, first-out method and consists of a standard set of medical supplies held in stock at all facilities.
Property and Equipment	Property and Equipment
	Property and equipment are stated at cost, less accumulated depreciation and amortization computed using the straight-line method over the estimated useful life of each asset. Leasehold improvements are amortized over the shorter of the noncancelable lease term or the estimated useful life of the improvements. When assets are retired, the cost and applicable accumulated depreciation are removed from the respective accounts, and the resulting gain or loss is recognized. Expenditures for normal repairs and maintenance are expensed as incurred. Material expenditures that increase the life of an asset are capitalized and depreciated over the estimated remaining useful life of the asset.  The estimated useful lives of depreciable fixed assets are as follows:
			Estimated useful life
			(in years)
	Computer equipment			3
	Automobiles			5
	Office equipment			5
	Medical equipment			5 to 7
	Leasehold improvement			4 to 10
	Buildings			15 to 20
	Amortization of assets acquired under capital leases is included as a component of depreciation and amortization expense in the accompanying consolidated statements of operations. Amortization is calculated using the straight-line method over the shorter of the useful lives or the term of the underlying lease agreements.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets
	Long-lived assets are reviewed for impairment whenever events or circumstances indicate that the carrying amount of an asset or group of assets might not be recoverable. The Company does not perform a periodic assessment of assets for impairment in the absence of such information or indicators. Conditions that would indicate a potential impairment include a significant decline in the observable market value of an asset or a significant change in the extent or manner in which an asset is used. The impairment review includes a comparison of future projected cash flows generated by the asset or group of assets with its associated net carrying value. If the net carrying value of the asset or group of assets exceeds expected cash flows (undiscounted and without interest charges), an impairment loss is recognized to the extent the carrying amount of the asset exceeds its fair value. The Company recorded long-lived asset impairment charges of $0.3 million for the year ending December 31, 2012, associated with the closing of the former corporate headquarters. There were no impairments recorded for the years ending December 31, 2014 or 2013.
Goodwill	Goodwill
	In accordance with the FASB ASC 805, Business Combinations, the purchase method of accounting requires that the excess of purchase price paid over the estimated fair value of identifiable tangible and intangible net assets of acquired businesses be recorded as goodwill. In accordance with the provisions of ASC 350, Intangibles—Goodwill and Other, goodwill is tested for impairment annually, and interim impairment tests are performed whenever an event occurs or circumstances change that indicate an impairment has more likely than not occurred. We have one reporting unit and goodwill is evaluated at that level. We evaluate impairment of goodwill by first performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than the carrying value. If it is concluded that this is the case, it is necessary to perform a two‑ step impairment test. The first step involves a comparison of the fair value of a reporting unit with its carrying amount. If the carrying value of the reporting unit exceeds its fair value, the second step involves a comparison of the implied fair value and the carrying amount of the goodwill of that reporting unit to determine the impairment charge, if necessary. We have established October 31 as the date for our annual impairment review.
	The Company estimates the fair value of its total invested capital using an income and market approach, reduced by interest bearing debt as of the valuation date. These valuations require management to make estimates and assumptions regarding industry economic factors and prospective financial information. There were no goodwill impairment charges recorded for the years ended December 31, 2014, 2013 and 2012.
Intangible Assets	Intangible Assets
	Intangible assets are recorded at their estimated fair values as of the date of acquisition. Intangible assets consist of trade and domain names and noncompete agreements. In accordance with ASC 350, Intangibles—Goodwill and Other , the Company reviews the intangible assets with indefinite lives, which include trade and domain names, at least annually for impairment, or more often if triggering events exist. Intangible assets with definite lives are reviewed for impairment if an indicator of impairment exists similar to long-lived assets. An impairment loss is recognized if the carrying amount of an intangible asset is not recoverable and its carrying amount exceeds its fair value. There were no impairment charges recorded on intangible assets for the years ended December 31, 2014, 2013 or 2012. Intangible assets with finite useful lives are amortized over their estimated useful life.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
	The carrying amounts of the Company's financial instruments, including cash, receivables, accounts payable and accrued liabilities approximate their fair value due to their relatively short maturities. At December 31, 2014 and 2013, the carrying value of the Company's long-term debt was based on the current interest rates and approximates its fair value.
Derivative Instruments and Hedging Activities	Derivative Instruments and Hedging Activities
	The Company recognizes all derivative instruments as either assets or liabilities in the balance sheet at their respective fair values. For derivatives not designated as a hedging instrument, changes in the fair value are recorded in net earnings immediately. For derivatives designated in hedging relationships, changes in the fair value are either offset through earnings against the change in fair value of the hedged item attributable to the risk being hedged or recognized in accumulated other comprehensive income, to the extent the derivative is effective at offsetting the changes in cash flows being hedged until the hedged item affects earnings.
	For the year ended December 31, 2012 and continuing through October 31, 2013, the Company maintained one derivative instrument that it did not designate as a hedge. As a result, changes in the fair value were recorded in earnings for this period. Beginning in November 2013, the Company only enters into derivative contracts that it intends to designate as a hedge of a forecasted transaction or the variability of cash flows to be received or paid related to a recognized asset or liability (cash flow hedge). For all hedging relationships, the Company formally documents the hedging relationship and its risk-management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument's effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company also formally assesses, both at the inception of the hedging relationship and on an ongoing basis, whether the derivatives that are used in hedging relationships are highly effective in offsetting changes in cash flows of hedged transactions. For derivative instruments that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported as a component of other comprehensive income and reclassified into earnings in the same period or years during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current earnings.
	The Company discontinues hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedged risk, the derivative expires or is sold, terminated, or exercised or the cash flow hedge is redesignated because a forecasted transaction is not probable of occurring.
	In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in its fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company discontinues hedge accounting and recognizes immediately in earnings gains and losses that were accumulated in other comprehensive income related to the hedging relationship.
Lease Accounting	Lease Accounting
	The Company determines whether to account for its facility leases as operating or capital leases depending on the underlying terms of the lease agreement. This determination of classification is complex and requires significant judgment relating to certain information including the estimated fair value and remaining economic life of the facilities, the Company's cost of funds, minimum lease payments and other lease terms. The lease rates under the Company's lease agreements are subject to certain conditional escalation clauses that are recognized when probable or incurred and are based on changes in the consumer price index or certain operational performance measures. As of December 31, 2014, the Company leased 54 facilities, 53 of which the Company classified as operating leases and one of which the Company classified as a capital lease.
Income Taxes	Income Taxes
	We provide for income taxes using the asset and liability method. This approach recognizes the amount of federal, state and local taxes payable or refundable for the current year, as well as deferred tax assets and liabilities for the future tax consequence of events recognized in the consolidated financial statements and income tax returns. Deferred income tax assets and liabilities are adjusted to recognize the effects of changes in tax laws or enacted tax rates.
	A valuation allowance is required when it is more-likely-than-not that some portion of the deferred tax assets will not be realized. Realization is dependent on generating sufficient future taxable income.
	We file a consolidated federal income tax return. State income tax returns are filed on a separate, combined or consolidated basis in accordance with relevant state laws and regulations. LPs, LLPs, LLCs and other pass-through entities that we consolidate file separate federal and state income tax returns. We include the allocable portion of each pass-through entity’s income or loss in our federal income tax return. We allocate the remaining income or loss of each pass-through entity to the other partners or members who are responsible for their portion of the taxes.
	The (benefit) provision for income taxes totaled $(1.3) million, $0.7 million and $0.5 million for the years ended December 31, 2014, 2013 and 2012, respectively. The Company's estimate of the potential outcome of any uncertain tax positions is subject to management's assessment of relevant risks, facts, and circumstances existing at that time. The Company uses a more likely than not threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return.
	To the extent that the Company's assessment of such tax position changes, the change in estimate is recorded in the period in which the determination is made. The Company reports tax related interest and penalties as a component of the provision for income tax and operating expenses, respectively, if applicable. The Company has not recognized any uncertain tax positions.
Deferred Rent	Deferred Rent
	The Company records rent expense for operating leases on a straight-line basis over the life of the related leases. The Company has certain facility and equipment leases that allow for leasehold improvements allowances, free rent, and escalating rental payments. Straight-line expenses that are greater than the actual amount paid are recorded as deferred rent and amortized over the life of the lease.
Investments and Equity in Loss of Unconsolidated Joint Venture	Investment in Unconsolidated Joint Venture
	Investments in unconsolidated companies in which the Company exerts significant influence but does not control or otherwise consolidate are accounted for using the equity method. The Company has one such investment with an ownership interest of 49.9%.
	This investment is included as investment in unconsolidated joint venture in the accompanying consolidated balance sheets.
	Equity in net loss of unconsolidated joint venture consists of the Company’s share of the losses generated from its noncontrolling equity investment in one full-service healthcare hospital facility. Because these operations are central to the Company’s business strategy, equity in earnings of unconsolidated affiliates is classified as a component of operating income in the accompanying consolidated statements of operations. The Company has contracts to manage these facilities, which results in the Company having an active role in the operations of these facilities and devoting a significant portion of its corporate resources to the fulfillment of these management responsibilities.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
	In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard will become effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	In August 2014, the FASB issued new guidance related to the disclosures around going concern. The new standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early adoption is permitted. The Company does not believe the adoption of this guidance will have a material impact on its consolidated financial statements.

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2014
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of patient service revenue by major payor source	Patient service revenue before the provision for bad debts by major payor source for the years ended December 31, 2014, 2013 and 2012 were as follows (in thousands):
			2014			2013		2012
	Third-party payors, including patient portion		$	237,972		$	113,603	$	79,408
	Self-pay			5,326			1,357		1,569
	Total all payors		$	243,298		$	114,960	$	80,977
Table of percentage of patient service revenue by major payor source
		2014		2013		2012
	Payor:
	Blue Cross Blue Shield	27.6	%	28.0	%	29.1	%
	United HealthCare	23.6		26.5		26.0
	Aetna	19.3		21.0		22.1
	Cigna	14.3		11.2		11.0
	Other	15.2		13.3		11.8
		100.0	%	100.0	%	100.0	%
Schedule of estimated useful lives of assets
			Estimated useful life
			(in years)
	Computer equipment			3
	Automobiles			5
	Office equipment			5
	Medical equipment			5 to 7
	Leasehold improvement			4 to 10
	Buildings			15 to 20

PROPERTY_AND_EQUIPMENT_Tables

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT
Schedule of property and equipment	Property and equipment consisted of the following, as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Leasehold improvements	$	77,354	$	37,626
	Computer equipment		3,700		1,583
	Medical equipment		4,213		2,970
	Office equipment		4,307		760
	Automobiles		243		243
	Land		8,276		2,430
	Construction in progress		8,835		17,788
	Buildings		4,667		4,551
			111,595		67,951
	Less accumulated depreciation		-17,703		-5,864
	Property and equipment, net	$	93,892	$	62,087

INVESTMENT_IN_UNCONSOLIDATED_J1

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Tables)	12 Months Ended
	Dec. 31, 2014
PROPERTY AND EQUIPMENT
Schedule of Investments in and Advances to Affiliates, Schedule of Investments [Table Text Block]	Summarized unaudited financial information for the Company’s equity method investee is as follows (in thousands):
		Year ended
		December 31,
		2014
	Net patient service revenue	$	247
	Operating expenses:
	Salaries, wages and benefits		880
	General and administrative		469
	Other operating expenses		688
	Depreciation and amortization		12
	Total operating expenses		2,049
	Loss from operations		-1,802
	Other (expense) income:
	Interest expense		-1
	Total other (expense)		-1
	Net loss	$	-1,803
	Balance sheet information (as of December 31, 2014):
	Current assets	$	1
	Noncurrent assets		5
	Current liabilities		2
	Noncurrent liabilities		0.1

GOODWILL_AND_OTHER_INTANGIBLE_1

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2014
GOODWILL AND OTHER INTANGIBLE ASSETS
Table summarizing the changes in good will	The following table summarizes the change in goodwill during the years ended December 31, 2014 and 2013 (in thousands):
		2014		2013
	Balance at beginning of year	$	61,009		61,009
	Adjustments		—		—
	Balance at end of year	$	61,009	$	61,009
Table summarizing the changes in intangible assets	The following table summarizes the change in intangible assets during the years ended December 31, 2014 and 2013 (in thousands):
		Noncompete		Trade		Domain
		Agreements		Names		Names		Total
	Balance at December 31, 2012	$	6,675	$	9,300	$	7,600	$	23,575
	Additions		—		—		—		—
	Amortization		-1,780		—		—		-1,780
	Balance at December 31, 2013	$	4,895	$	9,300	$	7,600	$	21,795
	Additions		—		—		—		—
	Amortization		-1,780		—		—		-1,780
	Balance at December 31, 2014	$	3,115	$	9,300	$	7,600	$	20,015
Table summarizing the estimated amortization of noncompete agreements	As of December 31, 2014, the following table sets forth the estimated amortization of the noncompete agreements for the years ending December 31 (in thousands):
	2015	$	1,780
	2016		1,335

DERIVATIVE_INSTRUMENTS_AND_HED1

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	12 Months Ended
	Dec. 31, 2014
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES
Summary of the Company's derivative instruments	The following table summarizes the Company's derivative instruments as of December 31, 2014 and 2013 (in thousands):
			2014		2013
		Balance Sheet Location	Fair Value		Fair Value
	Derivative designated as hedging instruments
	Interest rate contracts	Other long-term assets	$	19	$	92

ACCOUNTS_PAYABLE_AND_ACCRUED_E1

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2014
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Summary of accounts payable and accrued expenses	Accounts payable and accrued expenses consisted of the following as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Accounts payable	$	14,133	$	9,405
	Accrued expenses		4,431		1,267
	Accrued tax distribution to LLC Unit holders		4,246		3,772
	Other		2,610		763
	Total accounts payable and accrued expenses	$	25,420	$	15,207

DEBT_Tables

DEBT (Tables)	12 Months Ended
	Dec. 31, 2014
DEBT
Summary of components of debt	The components of debt consisted of the following as of December 31, 2014 and 2013 (in thousands):
		2014		2013
	Term loan	$	75,000	$	75,000
	Delayed draw term loan		25,000		—
	Revolving credit		5,500
	Other financing agreements		1,298		504
			106,798		75,504
	Less current maturities		-1,816		-504
		$	104,982	$	75,000
Schedule of future aggregate maturities of long-term debt	Scheduled future aggregate maturities of principal of long-term debt are as follows: (in thousands):
	Years ending December 31,	Amount
	2015	$	1,816
	2016		2,763
	2017		5,000
	2018		97,219
		$	106,798

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2014
COMMITMENTS AND CONTINGENCIES
Contractual obligations	.
	Future minimum lease payments required under noncancelable operating leases and future minimum, capital lease payments as of December 31, 2014 were as follows (in thousands):
		Capital		Operating
	Years ending December 31,	leases		leases
	2015	$	522	$	26,318
	2016		533		25,249
	2017		544		22,993
	2018		554		18,984
	2019		565		15,899
	Thereafter		5,512		139,184
	Total future minimum lease payments	$	8,230	$	248,627
	Less: Amounts representing interest		-4,093
	Present value of minimum lease payments		4,137
	Current portion of capital lease obligations		81
	Long-term portion of capital lease payments	$	4,056

SUPPLEMENTAL_CASH_FLOW_INFORMA1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2014
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW AND SUPPLEMENTAL NONCASH ACTIVITIES [Tables]	Supplemental cash flow information and supplemental noncash activities consisted of the following for the years ended December 31, 2014, 2013 and 2012 (in thousands):
		2014		2013		2012
	Supplemental cash flow information:
	Interest paid	$	9,294	$	2,486	$	1,091
	Franchise taxes paid		680		530		296
	Supplemental noncash activities:
	Acquisition of property and equipment in accounts payable and accrued expenses	$	2,239	$	467	$	2,341
	Assets acquired through capital lease		287		3,911		—
	Note payable for other financing agreements		2,056		757		390
	Accrual of owner distributions		474		1,735		2,042

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of components of our (benefit) provision for income taxes	The components of our (benefit) provision for income taxes were as follows (in thousands):
			2014		2013		2012
	Current:
	Federal	$	-	$	-	$	-
	State		821		720		467
	Total Current Taxes		821		720		467
	Deferred:
	Federal		-2,123		-		-
	State		-24		-		-
	Total Deferred Taxes		-2,147		-		-
	Total Income tax (benefit) provision	$	-1,326	$	720	$	467
Schedule of reconciliation of our income tax (benefit) expense	The reconciliation of our income tax (benefit) expense computed at the U.S. federal statutory tax rate to the actual income tax (benefit) expense is as follows (in thousands):
			2014		2013		2012
	Expense derived by applying the Federal Income tax rate to income (loss) before taxes	$	-6,509	$	-792	$	1,284
	Tax applicable to pass-through entities		4,631		792		-1,284
	State Income Tax, net of federal benefit		534		-		-
	Investment in Partnership (Nondeductible expenses)		18		-		-
		$	-1,326	$	-	$	-
Schedule of components of our deferred tax assets and liabilities	Significant components of our deferred tax assets and liabilities are as follows (in thousands):
			2014		2013		2012
	Deferred Tax Assets
	TRA Liability	$	8,125	$	-	$	-
	Investment in Partnership		20,940		-		-
	Net Operating Loss Carryforwards		4,957		-		-
	State Net Operating Loss Carryforwards		62		-		-
	Total Deferred Tax Assets	$	34,084	$	-	$	-

NET_INCOME_LOSS_PER_SHARE_Tabl

NET INCOME (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
SCHEDULE OF COMPUTATION OF BASIC AND DILUTED NET LOSS PER COMMON SHARE [Tables]
		2014		2013		2012
	Numerator
	Net loss attributable to Adeptus Health Inc.	$	-3,351	$	—	$	—
	Denominator:
	Class A common share-weighted average shares		9,845,016		—		—
	Effect of dilutive securities:
	Restricted shares		—		—		—
	Denominator for diluted net loss per Class A common share-weighted average shares		9,845,016		—		—
	Net loss attributable to Adeptus Health Inc. per Class A common share - Basic	$	-0.34	$	—	$	—
	Net loss attributable to Adeptus Health Inc. per Class A common share - Diluted	$	-0.34	$	—	$	—

SELECTED_QUARTERLY_FINANCIAL_D1

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	12 Months Ended
	Dec. 31, 2014
Quarterly Financial Information Disclosure [Abstract]
Selected unaudited quarterly statements of operationos data
		Three months ended
		December 31,		September 30,		June 30,		March 31,		December 31,		September 30,		June 30,		March 31,
		2014		2014		2014		2014		2013		2013		2013		2013
		(in thousands, except per share data)
	Patient service revenue	$	80,290	$	66,533	$	51,946	$	44,529	$	38,885	$	25,947	$	26,831	$	23,297
	Provision for bad debt		-10,234		-8,934		-7,708		-5,748		-5,173		-2,310		-2,333		-2,261
	Net patient service revenue		70,056		57,599		44,238		38,781		33,712		23,637		24,498		21,036
	Management and contract services revenue		20		—		—		—		—		—		—		—
	Total net operating revenue		70,076		57,599		44,238		38,781		33,712		23,637		24,498		21,036
	(Loss) income from operations		-139		-1,079		-5,072		-341		504		-599		1,401		-415
	Net (loss) income		-1,477		-3,598		-9,429		-2,767		-1,974		-1,511		1,336		-835
	Less: Net (loss) income attributable to non-controlling interest		-1,739		-2,001		-7,413		-2,767		-1,974		-1,511		1,336		-835
	Net income (loss) attributable to Adeptus Health Inc.	$	262	$	-1,597	$	-2,016	$	—	$	—	$	—	$	—	$	—
	Net loss per share of Class A common stock:
	Basic and Diluted	$	0.03	$	-0.16	$	-0.21	$	—	$	—	$	—	$	—	$	—

ORGANIZATION_Details

ORGANIZATION (Details) (USD $)	0 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 24, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
		facility	facility	facility
Ownership, voting power and economic interest
Number of emergency room facilities (in facilities)		55	26	14
Issuance of Class A shares in IPO, shares		735,000
Shares sold by a significant shareholder		313,586
Shares sold by the Company with specific purpose of proceeds		421,414
Dividends paid to existing owners	$60,000
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		52.30%
Common Class A [Member]
Ownership, voting power and economic interest
Issuance of Class A shares in IPO, shares		4,900,000
Conversion ratio		1
Common Class B [Member]
Ownership, voting power and economic interest
Conversion ratio		1
Adeptus Health LLC [Member]
Ownership, voting power and economic interest
Dividends paid to existing owners		60,000
Adeptus Health LLC [Member] | Common Class A [Member]
Ownership, voting power and economic interest
Shares converted		4,895,521

SUMMARY_OF_SIGNIFICANT_ACCOUNT3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Patient service revenue by major payor source
Patient service revenue	$80,290	$66,533	$51,946	$44,529	$38,885	$25,947	$26,831	$23,297	$243,298	$114,960	$80,977
Third Party Payor [Member]
Patient service revenue by major payor source
Patient service revenue									237,972	113,603	79,408
Self Pay [Member]
Patient service revenue by major payor source
Patient service revenue									$5,326	$1,357	$1,569

SUMMARY_OF_SIGNIFICANT_ACCOUNT4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Major payor revenues and receivables
Number of MultiPlan arrangements	2
Major Third Party Payors [Member]
Major payor revenues and receivables
Number of major third-party payors	4
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member]
Major payor revenues and receivables
Percentage of Company total	100.00%	100.00%	100.00%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | Major Third Party Payors [Member]
Major payor revenues and receivables
Percentage of Company total	84.80%	86.70%	88.20%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | Blue Cross Blue Shield [Member]
Major payor revenues and receivables
Percentage of Company total	27.60%	28.00%	29.10%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | United Health Care [Member]
Major payor revenues and receivables
Percentage of Company total	23.60%	26.50%	26.00%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | Aetna [Member]
Major payor revenues and receivables
Percentage of Company total	19.30%	21.00%	22.10%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | Cigna [Member]
Major payor revenues and receivables
Percentage of Company total	14.30%	11.20%	11.00%
Sales Revenue Services Net [Member] | Customer Concentration Risk [Member] | Other Payors [Member]
Major payor revenues and receivables
Percentage of Company total	15.20%	13.30%	11.80%
Accounts Receivable [Member] | Credit Concentration Risk [Member] | Major Third Party Payors [Member]
Major payor revenues and receivables
Percentage of Company total	80.00%	79.00%

SUMMARY_OF_SIGNIFICANT_ACCOUNT5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
	facility
Derivative Instruments and Hedging Activities
Cash equivalents	$0
Percentage of base rent on which letter of credit is issued	50.00%
Restricted cash	4,795,000	294,000
Fee adjustments	137,100,000	62,500,000	44,500,000
Bad debt write-offs	24,800,000	10,100,000	7,700,000
Charity care, percent of patient service revenue	8.6	7	2
Advertising expense	5,400,000	2,100,000	1,000,000
Impairment charges of long-lived assets	0	0	300,000
Goodwill impairment charges	0	0	0
Number of facilities leased	54
Number of facilities classified as operating leases	53
Number of leased facilities capitalized (in facilities)	1
(Benefit) provision for income taxes	($1,326,000)	$720,000	$467,000
Investment ownership percentage	49.90%
Nondesignated [Member]
Derivative Instruments and Hedging Activities
Number of derivative instruments maintained	1
Computer Equipment [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	3 years
Automobiles [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	5 years
Office Equipment [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	5 years
Medical Equipment [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	5 years
Medical Equipment [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	7 years
Leasehold Improvements [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	4 years
Leasehold Improvements [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	10 years
Building [Member] | Minimum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	15 years
Building [Member] | Maximum [Member]
Derivative Instruments and Hedging Activities
Estimated useful lives of assets	20 years

PROPERTY_AND_EQUIPMENT_Details

PROPERTY AND EQUIPMENT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment
Property and equipment	$111,595,000	$67,951,000
Less accumulated depreciation	17,703,000	5,864,000
Property and equipment, net	93,892,000	62,087,000
Assets under capital leases	4,200,000	3,900,000
Accumulated depreciation associated with capital lease assets	300,000	23,000
Leasehold Improvements [Member]
Property and Equipment
Property and equipment	77,354,000	37,626,000
Computer Equipment [Member]
Property and Equipment
Property and equipment	3,700,000	1,583,000
Medical Equipment [Member]
Property and Equipment
Property and equipment	4,213,000	2,970,000
Office Equipment [Member]
Property and Equipment
Property and equipment	4,307,000	760,000
Automobiles [Member]
Property and Equipment
Property and equipment	243,000	243,000
Land [Member]
Property and Equipment
Property and equipment	8,276,000	2,430,000
Asset Under Construction [Member]
Property and Equipment
Property and equipment	8,835,000	17,788,000
Building [Member]
Property and Equipment
Property and equipment	$4,667,000	$4,551,000

INVESTMENT_IN_UNCONSOLIDATED_J2

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Details) (Dignity Health Arizona General Hospital [Member])	12 Months Ended
	Dec. 31, 2014
	item
	sqft
Dignity Health Arizona General Hospital [Member]
Schedule of Equity Method Investments [Line Items]
Area of hospital facility (in square feet)	39,000
Number of inpatient rooms	16
Number of operating rooms	2

INVESTMENT_IN_UNCONSOLIDATED_J3

INVESTMENT IN UNCONSOLIDATED JOINT VENTURE (Details 2) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity method investment information
Net patient service revenue	$70,056,000	$57,599,000	$44,238,000	$38,781,000	$33,712,000	$23,637,000	$24,498,000	$21,036,000	$210,674,000	$102,883,000	$72,601,000
Operating expenses:
Salaries, wages and benefits									136,498,000	65,244,000	41,754,000
General and administrative									37,604,000	17,436,000	12,805,000
Other operating expenses									27,329,000	11,185,000	7,493,000
Loss (gain) from the disposal or impairment of assets									-42,000	207,000	652,000
Depreciation and amortization									15,037,000	7,920,000	4,640,000
Total operating expenses									216,426,000	101,992,000	67,344,000
(Loss) income from operations	-139,000	-1,079,000	-5,072,000	-341,000	504,000	-599,000	1,401,000	-415,000	-6,632,000	891,000	5,257,000
Other (expense) income:
Interest expense									-11,966,000	-2,827,000	-1,056,000
Change in fair market value of derivatives										112,000	-533,000
Total other (expense)									-11,966,000	-3,155,000	-1,589,000
Loss before (benefit) provision for income taxes									-18,598,000	-2,264,000	3,668,000
(Benefit) provision for income taxes									-1,326,000	720,000	467,000
Net (loss) income	-1,477,000	-3,598,000	-9,429,000	-2,767,000	-1,974,000	-1,511,000	1,336,000	-835,000	-17,272,000	-2,984,000	3,201,000
Balance sheet information:
Assets, Current	65,643,000				33,071,000				65,643,000	33,071,000
Liabilities, Current	41,445,000				25,424,000				41,445,000	25,424,000
Equity Method Investee [Member]
Equity method investment information
Net patient service revenue									247,000
Operating expenses:
Salaries, wages and benefits									880,000
General and administrative									469,000
Other operating expenses									688,000
Depreciation and amortization									12,000
Total operating expenses									2,049,000
(Loss) income from operations									-1,802,000
Other (expense) income:
Interest expense									-1,000
Total other (expense)									-1,000
Net (loss) income									-1,803,000
Balance sheet information:
Assets, Current	1,000								1,000
Assets, Noncurrent	5,000								5,000
Liabilities, Current	2,000								2,000
Liabilities, Noncurrent	$100								$100

GOODWILL_AND_OTHER_INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Goodwill
Balance at beginning of year	$61,009	$61,009
Balance at end of year	61,009	61,009
Changes in iintangible assets
Balance at beginning of period	21,795	23,575
Amortization	-1,780	-1,780
Balance at end of period	20,015	21,795
Future Amortization
2015	1,780
2016	1,335
Trade Names [Member]
Changes in iintangible assets
Balance at beginning of period			9,300
Balance at end of period	9,300	9,300	9,300
Internet Domain Names [Member]
Changes in iintangible assets
Balance at beginning of period			7,600
Balance at end of period	7,600	7,600	7,600
Noncompete Agreements [Member]
Changes in iintangible assets
Balance at beginning of period	4,895	6,675
Amortization	-1,780	-1,780
Balance at end of period	$3,115	$4,895

DERIVATIVE_INSTRUMENTS_AND_HED2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Details) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013	Dec. 31, 2014	31-May-12
Derivatives, Fair Value [Line Items]
Deferred losses included in other comprehensive income				$74,000
Gain (loss) on the change in fair value of the swap agreement	112,000	-533,000
Designated As Hedging Instrument [Member] | Other Noncurrent Assets [Member]
Derivatives, Fair Value [Line Items]
Fair Value	92,000			19,000
Interest Rate Swap [Member] | Nondesignated [Member] | Cash Flow Hedging [Member] | Forward Contracts [Member]
Derivatives, Fair Value [Line Items]
Notional amount					24,000,000
Fixed interest rate	1.20%
Interest Rate Cap [Member] | Designated As Hedging Instrument [Member] | Cash Flow Hedging [Member]
Derivatives, Fair Value [Line Items]
Number of agreements				1
Notional amount				37,500,000
Capped interest rate				3.00%
Cost			$90,000

ACCOUNTS_PAYABLE_AND_ACCRUED_E2

ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
ACCOUNTS PAYABLE AND ACCRUED EXPENSES
Accounts payable	$14,133	$9,405
Accrued expenses	4,431	1,267
Accrued tax distribution to LLC unit holders	4,246	3,772
Other	2,610	763
Total accounts payable and accrued expenses	$25,420	$15,207

DEBT_Details

DEBT (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]
Less current maturities	$1,816	$504
Long-term debt, less current maturities	104,982	75,000
Insurance Financing Agreement [Member]
Debt Instrument [Line Items]
Debt, long-term and short-term combined amount	1,298	504
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Debt, long-term and short-term combined amount	106,798	75,504
Secured Debt [Member]
Debt Instrument [Line Items]
Debt, long-term and short-term combined amount	75,000	75,000
Delayed Draw Term Loan [Member]
Debt Instrument [Line Items]
Debt, long-term and short-term combined amount	25,000
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Debt, long-term and short-term combined amount	$5,500

DEBT_Details_2

DEBT (Details 2) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 11, 2014	Oct. 31, 2013	Mar. 31, 2014	Jun. 30, 2014
Line of Credit Facility
Maximum aggregate funding amount permitted						$255,000,000
Proceeds from long-term borrowings	99,457,000	102,000,000	25,700,000
Senior Secured Credit Facility Original Agreement [Member]
Line of Credit Facility
Debt instrument face amount					75,000,000
Senior Secured Credit Facility Second Amendment [Member]
Line of Credit Facility
Proceeds from long-term borrowings				75,000,000
Senior Secured Credit Facility [Member]
Line of Credit Facility
Unused line fee	0.50%
Annual Agency fee	100,000
Senior Secured Credit Facility [Member] | Debt Instrument Base Rate Loans [Member] | Prime Rate [Member]
Line of Credit Facility
Description of debt instrument variable rate basis	prime rate
Senior Secured Credit Facility [Member] | Debt Instrument Base Rate Loans [Member] | Federal Funds Effective Swap Rate [Member]
Line of Credit Facility
Description of debt instrument variable rate basis	federal funds
Basis spread on variable rate interest	0.50%
Margin added to variable interest rate	6.50%
Senior Secured Credit Facility [Member] | Debt Instrument Libor Rate Loans [Member]
Line of Credit Facility
Description of debt instrument variable rate basis	LIBOR
Senior Secured Credit Facility [Member] | Debt Instrument Libor Rate Loans [Member] | London Interbank Offered Rate L I B O R [Member]
Line of Credit Facility
Basis spread on variable rate interest	1.00%
Margin added to variable interest rate	7.50%
Delayed Draw Term Loan [Member]
Line of Credit Facility
Maximum borrowing capacity					165,000,000
Debt instrument term					18 months
Draw fee	1.00%
Remaining borrowing capacity	80,200,000
Delayed Draw Term Loan [Member] | Senior Secured Credit Facility Second Amendment [Member]
Line of Credit Facility
Maximum borrowing capacity							75,000,000
Amount of principal which will be used for specified distributions							60,000,000
Amount of principal which will be used to repay certain revolving loans							10,000,000
Revolving Credit Facility [Member]
Line of Credit Facility
Maximum borrowing capacity					10,000,000
Remaining borrowing capacity	$4,000,000	$9,500,000

DEBT_Details_3

DEBT (Details 3) (Secured Debt [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014
Minimum [Member]
Line of Credit Facility
Periodic principal payment	$0.50
Maximum [Member]
Line of Credit Facility
Periodic principal payment	$0.90

DEBT_Details_4

DEBT (Details 4) (USD $)	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Oct. 31, 2013	Oct. 31, 2012
Insurance Financing Agreement July 2014 [Member]
Finance Agreement
Debt instrument face amount	1,900,000
Insurance Financing Agreement July 2014 [Member] | Minimum [Member]
Finance Agreement
Stated interest rate	2.49%
Debt instrument term	9 months
Insurance Financing Agreement July 2014 [Member] | Maximum [Member]
Finance Agreement
Stated interest rate	3.25%
Debt instrument term	11 months
Insurance Financing Agreement October2013 [Member]
Finance Agreement
Debt instrument face amount		800,000
Stated interest rate		1.93%
Debt instrument term		9 months
Insurance Financing Agreement October2012 [Member]
Finance Agreement
Debt instrument face amount			$400,000
Stated interest rate			3.48%
Debt instrument term			11 months

DEBT_Details_5

DEBT (Details 5) (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future aggregate maturities of long term debt
2015	$1,816
2016	2,763
2017	5,000
2018	97,219
Total	$106,798

TRANSACTIONS_WITH_RELATED_PART1

TRANSACTIONS WITH RELATED PARTIES (Details) (USD $)	12 Months Ended			1 Months Ended	0 Months Ended	13 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014	Nov. 22, 2013	Dec. 31, 2014
Sponsor Of Company [Member] | Management Services And Reimbursement Of Certain Expenses [Member]
Agreement provisions
Payments	$800,000	$600,000	$600,000
Sponsor Of Company [Member] | Termination Of Advisory Services Agreement [Member]
Agreement provisions
Payments				2,000,000
Various Related Party Vendors [Member] | Contractor Services [Member]
Agreement provisions
Payments	60,000	60,000	100,000
Io Phoenix One [Member] | License And Master Services Agreement For Data Centers [Member]
Agreement provisions
Monthly payment						4,000
lnital term of agreement					36 months
Total amount payable	$148,000					$148,000

EMPLOYEE_BENEFIT_PLANS_Details

EMPLOYEE BENEFIT PLANS (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Employer contributions	$0.50	$0.30
Contributions approved by board of directors	$0.90

COMMITMENTS_AND_CONTINGENCIES_1

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Uninsured Risk [Member]
Loss Contingencies
Accrual for incurred but not reported claims	$700,000	$700,000
Workers Compensation Insurance [Member]
Loss Contingencies
Maximum amount of worker's compensation claims	1,000,000
Policy limit	1,000,000
Professional Malpractice Liability [Member]
Loss Contingencies
Worker's compensation expense	300,000	70,000	30,000
Maximum professional liability insurance per incident	1,000,000
Maximum professional liability insurance per facility	3,000,000
Maximum professional liability aggregate policy limit	$20,000,000

COMMITMENTS_AND_CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details 2) (USD $)	12 Months Ended			1 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014
	facility
Other Commitments
Number of leased facilities capitalized (in facilities)	1
Lease expense	$15.20	$4.50	$2.10
Master Funding And Development Agreement [Member]
Other Commitments
Maximum number of facilities (in facilities)	25
Maximum funding per agreement	100
Initial term of lease	15 years
Number of lease renewal options (in leases)	3
Lease renewal terms	5 years
Additional Master Funding And Development Agreement [Member]
Other Commitments
Maximum funding per agreement				150
Corporate Headquarters [Member]
Other Commitments
Square footage leased (in square feet)	80,000
Lease expense	$1.40	$0.70	$0.10

COMMITMENTS_AND_CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity
2015	$522
2016	533
2017	544
2018	554
2019	565
Thereafter	5,512
Total future minimum lease payments	8,230
Less: Amounts representing interest	-4,093
Present value of minimum lease payments	4,137
Current maturities of capital lease obligations	81	58
Capital lease obligations, less current maturities	$4,056	$3,849

COMMITMENTS_AND_CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 4) (USD $)	12 Months Ended			1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity
2015	$26,318,000
2016	25,249,000
2017	22,993,000
2018	18,984,000
2019	15,899,000
Thereafter	139,184,000
Total future minimum lease payments	248,627,000
Leases, Operating [Abstract]
Lease expense	15,200,000	4,500,000	2,100,000
Georgetown Texas [Member]
Leases, Operating [Abstract]
Lease termination fees				$200,000

SUPPLEMENTAL_CASH_FLOW_INFORMA2

SUPPLEMENTAL CASH FLOW INFORMATION (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Supplemental Cash Flow Information [Abstract]
Interest paid	$9,294	$2,486	$1,091
Franchise taxes paid	680	530	296
Noncash Investing and Financing Items [Abstract]
Acquisition of property and equipment in accounts payable and accrued expenses	2,239	467	2,341
Assets acquired through capital lease	287	3,911
Notes payable for insurance premiums	2,056	757	390
Accrual of owner distributions	$474	$1,735	$2,042

STOCK_BASED_COMPENSATION_Detai

STOCK BASED COMPENSATION (Details) (USD $)	12 Months Ended			0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 24, 2014	Jul. 31, 2014
Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Compensation expense	$1,000,000	$600,000	$300,000
Performance Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Unrecognized compensation expense	100,000
Omnibus Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Total number of shares which may be issued	1,033,500
Omnibus Incentive Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Granted weighted average exercise price (in dollars per share)	$24.33
Omnibus Incentive Plan [Member] | Restricted Stock [Member] | Non Employee Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Restricted shares granted				11,934
Omnibus Incentive Plan [Member] | Restricted Stock [Member] | Certain employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Restricted shares granted					35,856
Vesting period					4 years
Omnibus Incentive Plan [Member] | Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Unrecognized compensation cost related to share-based awards	300,000
Weighted average recognition period of unrecognized compensation cost	2 years
Aggregate intrinsic value	900,000
Legacy Equity Compensation Plan [Member] | Time Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Risk-free interest rate assumption		0.93%	0.72%
Volatility assumption		25.00%	30.00%
Dividend rate assumption		0.00%	0.00%
Weighted average fair value of incentive units granted		1,262	204
Legacy Equity Compensation Plan [Member] | Time Based Restricted Stock Units [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award
Vesting period	4 years
Legacy Equity Compensation Plan [Member] | Performance Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology
Weighted average fair value of incentive units granted		$384	$37

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
State	$821	$720	$467
Total Current Taxes	821	720	467
Deferred:
Federal	-2,123
State	-24
Total Deferred Taxes	-2,147
Total Income tax (benefit) provision	-1,326	720	467
Reconciliation of income tax (benefit) expense
Benefit derived by applying the Federal Income tax rate to loss before taxes	-6,509	-792	1,284
Tax applicable to pass-through entities	4,631	792	-1,284
State Income Tax, net of federal benefit	534
Investment in Partnership (Nondeductible expenses)	18
Total Income tax (benefit) provision	-1,326	720	467
Deferred Tax Assets
TRA Liability	8,125
Investment in Partnership	20,940
Net Operating Loss Carryforwards	4,957
State Net Operating Loss Carryforwards	62
Total Deferred Tax Assets	34,084
Federal
Deferred Tax Assets
Net Operating Loss Carryforwards	$5,000

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014
Agreement provisions
Payable to related parties pursuant to tax receivable agreement	$30,039
Deferred tax asset composition
Deferred tax asset	34,084
Post Ipo Unit Holders And Merged Owner [Member] | Tax Receivable Agreement [Member]
Agreement provisions
Percentage of deemed tax benefits required to be paid	85.00%
Payable to related parties pursuant to tax receivable agreement	$30,000

NET_INCOME_LOSS_PER_SHARE_Deta

NET INCOME (LOSS) PER SHARE (Details) (USD $)	3 Months Ended			12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Dec. 31, 2014
Initial public offering
Common stock, shares outstanding	4,895,521			4,895,521
Common stock, shares issued	4,900,000			4,900,000
Numerator
Net loss attributable to Adeptus Health Inc.	$262	($1,597)	($2,016)	($3,351)
Denominator:
Denominator for basic net loss per Class A common share-weighted average shares				9,845,016
Effective of dilutive securities:
Denominator for diluted net loss per Class A common share-weighted average shares				9,845,016
Net loss attributable to Adeptus Health Inc. per Class A common share - Basic				($0.34)
Net loss attributable to Adeptus Health Inc. per Class A common share - Diluted				($0.34)
Director [Member] | Restricted Stock [Member]
Initial public offering
Restricted shares				11,934
Certain employees [Member] | Restricted Stock [Member]
Initial public offering
Restricted shares				38,856
Common Class A [Member]
Initial public offering
Common stock, shares outstanding	9,845,016			9,845,016
Common stock, shares issued	9,845,016			9,845,016
Denominator:
Denominator for basic net loss per Class A common share-weighted average shares				9,845,016
Effective of dilutive securities:
Denominator for diluted net loss per Class A common share-weighted average shares				9,845,016
Net loss attributable to Adeptus Health Inc. per Class A common share - Basic				($0.34)
Net loss attributable to Adeptus Health Inc. per Class A common share - Diluted				($0.34)

SELECTED_QUARTERLY_FINANCIAL_D2

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Patient service revenue	$80,290	$66,533	$51,946	$44,529	$38,885	$25,947	$26,831	$23,297	$243,298	$114,960	$80,977
Provision for bad debt	-10,234	-8,934	-7,708	-5,748	-5,173	-2,310	-2,333	-2,261	-32,624	-12,077	-8,376
Net patient service revenue	70,056	57,599	44,238	38,781	33,712	23,637	24,498	21,036	210,674	102,883	72,601
Management and contract services revenue	20								20
Total net operating revenue	70,076	57,599	44,238	38,781	33,712	23,637	24,498	21,036	210,694	102,883	72,601
(Loss) income from operations	-139	-1,079	-5,072	-341	504	-599	1,401	-415	-6,632	891	5,257
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	-1,477	-3,598	-9,429	-2,767	-1,974	-1,511	1,336	-835	-17,272	-2,984	3,201
Less: Net loss attributable to the non-controlling interest	-1,739	-2,001	-7,413	-2,767	-1,974	-1,511	1,336	-835	-13,921	-2,984	3,201
Net loss attributable to Adeptus Health Inc.	$262	($1,597)	($2,016)						($3,351)
Basic and diluted (in dollars per share)	$0.03	($0.16)	($0.21)